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Thesis Abstract 
Background 
Since the 1850s, parathyroid surgery continues to evolve through improved 
understanding of the pathophysiology. Dialysis dependant end stage renal 
failure (ESRF), the major cause of secondary hyperparathyroidism continues 
to rise in the western world. Other than renal transplantation, 
parathyroidectomy may provide a substantial cure for longstanding renal 
hyperparathyroidism in dialysis dependant patients. In 2004, cinacalcet was 
introduced as an alternative to the surgical management of renal 
hyperparathyroidism. However, cinacalcet was withdrawn from Australia’s 
Pharmaceutical Benefits Scheme (PBS) in 2015, as the EVOLVE study 
failed to demonstrate a statistically significant reduction in the time to death, 
or non-fatal cardiovascular events in those treated with cinacalcet with renal 
hyperparathyroidism. This led to a re-emergence in parathyroidectomy. 
Additionally in our institution, patients who had been on cinacalcet, and 
subsequently underwent parathyroidectomy because of refractory disease or 
intolerance to cinacalcet, were noted to experience greater hyperkalaemia 
and hypocalcaemia in the intraoperative and immediate postoperative period.  
 
Aims  
 To review the engrossing history of the discovery and progression of 
parathyroid surgery since the 19
th
 century; 
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 To correlate the embryology, anatomy, histology, physiology and 
pathophysiology of parathyroid glands in end stage renal failure; 
 To provide up to date review in regards to investigation and the 
surgical management of renal hyperparathyroidism; 
 Conduct a cohort study on the association of cinacalcet use with 
greater likelihood of intraoperative and immediate postoperative 
hyperkalaemia and hypocalcaemia following parathyroidectomy in 
renal hyperparathyroidism. 
 
Methods 
Literature reviews utilizing MEDLINE and Cochrane review databases, life 
science journals and textbooks were utilized. Hospital medical records from 
The Canberra Hospital were studied to collect data on the cohort case series. 
Analysis of data was performed using SPSS Statistics and Microsoft Excel. 
 
Results 
Sir Richard Owen is reputed to be the first person to discover the existence 
of parathyroid glands when examining a rhinoceros in 1852. In the spirit of 
mortui vivos docent, Captain Charles Martell in the 1930s had significantly 
increased our understanding of the existence of ectopic locations of 
parathyroid glands, as well as operative planning. The physiology and 
pathophysiology of parathyroid glands in chronic renal failure is 
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multifaceted, with a complex interplay between bone, kidneys, intestine, 
vitamin D, potassium, phosphate and magnesium. There are a range of 
investigative strategies for localizing parathyroid glands, often yielding 
greater sensitivity and specificity when utilizing a combination of imaging 
tools. The choice of operative strategy for parathyroidectomy is often 
influenced by surgeon’s preference and the institution’s resources, due to 
paucity of good randomized trials and meta-analysis. Finally, our cohort 
study has shown that prior cinacalcet use was linked closely with severe 
intraoperative and immediate postoperative hyperkalaemia, and greater 
hypocalcaemia compared to control patients who underwent 
parathyroidectomy for renal hyperparathyroidism.  
 
Conclusions 
The continued inquiry into the basic sciences around renal 
hyperparathyroidism ensures that we are able to question traditional 
protocols, and practice the best evidence based medicine. From this, 
cinacalcet emerged to change the medical and surgical landscape in the 
treatment of hyperparathyroidism. The results of the cohort study led to 
development of a protocol for the perioperative management of renal 
hyperparathyroidism in cinacalcet treated patients requiring 
parathyroidectomy. 
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 “Better is possible. It does not take genius. It takes diligence. It takes moral 
clarity. It takes ingenuity. And above all, it takes a willingness to try” 
- Atul Gawande 
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Chapter 1: History of the Parathyroid 
Glands and Parathyroidectomy 
 
The discovery of parathyroid glands and the introduction 
of parathyroidectomy (PTX) has a rich historical background and involved 
medical doctors and scientists of renown. It also uniquely paralleled the 
history of surgery in general, initially influenced by observations of 
anatomists, pathologists and surgeons in Europe, and followed by 
contributions of several American teams. There is every reason to believe 
that diseases of the parathyroid glands affected occasional individuals in 
every period and culture in the history of mankind (Eknoyan, 
1995). Although associated clinical features were described in early medical 
literature prior to the discovery of the parathyroid 
glands, their presence remained unnoticed until the mid-19th century. In fact, 
the parathyroid glands are credited to be the last mammalian organ 
discovered to be visible to the naked eye (Delbridge and Palazzo, 2007). The 
mechanisms involved in hyperparathyroidism were not fully appreciated 
until the early-20th century, and were a classic example of the slow 
progression of endocrinology by trial and error via laboratory investigation, 
and the examination of individual cases (Giddings et al, 2009). The first 
intentional PTX with curative intent was largely acclaimed to occur in 1925, 
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and from then on, the field of PTX started to be defined, and continually be 
refined till the present day.  
 
In 1834, the Zoological Society of London purchased its first Great Indian 
Rhinoceros (Rhinoceros unicornis) for 1000 guineas. Following the 
animals’ death in 1849, Sir Richard Owen (Figure 1), Hunterian Professor 
and Conservator of the Royal College of Surgeons of England was given the 
uncommon opportunity to dissect the animal, which took place in the winter 
months of 1849 to 1850 at the Conservator’s resident quarters (Modari et al, 
2004).  
 
Figure 1. Sir Richard Owen (1804-1892), British Comparative Anatomist 
(Roher and Schulte, 2007) 
 
In his paper on the dissection in 1850 to the Zoological Society and later 
published in their Transactions in 1852, he described “a small, compact 
yellow glandular body that is attached to the thyroid where veins emerge”, 
subsequently known as the Glands of Owen (Rogers-Stevane and Kauffman, 
2008). The original preparation remains preserved in the Hunterian Museum 
at the College, consisting of part of the larynx, trachea and thyroid of the 
rhinoceros, with a parathyroid gland attached measuring 30×14×8cm to the 
upper extremity of the thyroid gland (Figure 2). This probably was the first 
description of the parathyroid glands. Afterwards, there were unconfirmed 
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reports of ‘parathyroid glands’ in humans made by Robert Remark in 1855 
and by Rudolf Virchow in 1863 (Rolleston, 1936). 
 
Figure 2. Sir Richard Owen’s original Indian rhinoceros specimen 
demonstrating the parathyroid gland (in arrow). Courtesy of Royal College 
of Surgeons of England, London 
 
Full credit was given to Swedish born Ivar Victor Sandstrőm (Figure 3), a 
25 year old medical student for identification, histologic description and 
naming of parathyroid glands, albeit claiming they were undeveloped 
embryologic portions of the thyroid gland.  He dedicated three of his 
postgraduate years as a prosector in the Department of Anatomy in Upsala, 
Sweden to dissect parathyroid glands from 50 human cadavers and other 
mammals (cats, dogs, horses, rabbits and ox) (Eknoyal, 1995). He described 
the colour, protean shapes and positions of the gland, and performed 
microscopic studies on fresh autopsy specimens using several staining 
techniques.  He named them “glandulae parathyroidae”.  
 
Figure 3. Ivar Victor Sandstrőm (Roher and Schulte, 2007) 
 
In the Upsala Läkarefőrenings Főrhandlinger 1880, he stated:  
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‘I encountered on the thyroid of a dog a small hardly hemp-seed sized 
structure which was included in the same capsule as the thyroid, but 
distinguished itself from it by a brighter colour. A superficial examination 
revealed an organ of a structure entirely different from that of the thyroid 
and particularly amply vascularized, because of which I considered it 
probable that here a vascular gland had been encountered, analogous to the 
carotid glands’ (Gley, 1891).  
 
Sandstrőm was also aware of the variability of their location, and further 
observed: 
“Although the glands were generally united with the thyroid by means of soft 
connective tissue, they were often movable against its capsule. Many of the 
glands are well defined fat lobules separated from the thyroid gland capsule. 
To each gland, there are one or more small arteriole branches from the 
inferior thyroid artery, and in the interstitial tissue there are often 
considerable fat cells and may be so numerous that the parenchyma of the 
gland appears only here and there in the spaces between the fat cells” 
(Sandstrőm, 1880). 
 
The significance of Sandstrőm’s discovery went relatively unnoticed 
internationally. His manuscript, with carefully detailed gross and 
microscopic drawings was rejected by famous German editors because of its 
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length. Later, his work was published in a local Swedish medical journal, 
Upsala Läkarefőrenings Főrhandlingar. Sandstrőm did not receive the 
acclaim he deserved during a short lifetime, later committing suicide (Dolev, 
1987).  
 
The contracture of the extremities, with or without peculiar seizures was 
detailed over 150 years ago when Corvisard introduced the term “tetany” for 
the first time in 1852 (Toneto et al, 2016). Trousseau, in 1862 and Chvostek, 
in 1876 defined specific clinical signs that characterize it, without defining 
its origin (Toneto et al, 2016). The combination of these tetanic symptoms 
was first described by Anton Wolfer in 1879, in a patient undergoing total 
thyroidectomy by Billroth (Toneto et al, 2016). In 1891, Eugene Gley, 
Professor of Physiology at the College de France in Paris, observed that 
when he injured animal parathyroids while leaving the thyroid intact, he 
observed tetany and reported a possible connection between PTX and tetany. 
His report was well received by European thyroid surgeons, and his results 
confirmed by Giulio Vassale and Francesco Generali in 1897, who found 
that extirpating both the thyroid and parathyroid glands in animals caused a 
milder clinical syndrome and less rapidly fatal outcome than was true for 
simple PTX (Dolev, 1987). Their conclusion was that after PTX alone, the 
animals were poisoned, believing the function of parathyroid glands was to 
detoxify toxins, however with thyroidectomy added to the surgery, the 
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metabolic rate decreased and this caused a decreased production of 
toxins (Idem, 1900). This was the basis for the detoxification theory which 
remained accepted until the mid-1920s (Vassale and Generali, 1896).   
 
In 1891, Frederick von Recklinghausen reported a series of patients with 
bone disease demonstrating pathological fractures, brown tumours and 
skeletal cystic disease. This group of patients were subsequently termed 
‘osteitis fibrosa cystica’, and although von Recklinghausen made an 
important clinical observation, he did not correlate this bone disease with 
hyperparathyroidism (Modarai et al, 2004).   
 
The relationship between serum calcium, parathyroid glands and tetany was 
not fully understood until the early 1900s. William MacCallum is credited to 
be the first to convincingly demonstrate a link between hypocalcaemia 
and tetany in 1909 (Dolev, 1987). MacCallum and Carl Voegtlin 
demonstrated that post-parathyroidectomy tetany could be corrected by a 
parathyroid extract or by injection of calcium, but not potassium or sodium. 
They further demonstrated a decrease in tissue calcium in tetany, 
hyperexcretion of calcium in the urine or faeces, and increased urinary 
excretion of nitrogen (Dolev, 1987). In his classic experiment, MacCallum 
used dialysis to remove calcium from blood, injected it into tetanic animals, 
and observed that these animals remained tetanic when compared with 
animals given normal blood. He concluded that:  
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‘The tetany of parathyroidectomy…is due to lack of calcium’ (MacCallum et 
al, 1914) 
 
Despite his authoritative statement, it was not universally accepted until 
much later in the 20th century, due to the popularity of the detoxification 
theory (Giddings et al, 2009).  The first to suggest a connection between 
parathyroid gland disease, and diseases of the bone was from the work of 
Viennese pathologist Jacob Erdheim. He noted parathyroid hyperplasia in 
three patients with osteomalacia, and in a series of experiments in 1906, he 
selectively damaged rat parathyroid glands with cautery and observed tetany, 
as well as poor calcification of rat teeth (Eknoyan, 1995, Giddings et al, 
2009, Rogers-Stevane and Kauffman, 2008). He went on to describe that this 
demineralisation of teeth could be reversed by allografting parathyroid 
tissue. Erdheim concluded the changes in the parathyroid glands were a 
compensatory response to the bone disease and thus beneficial (Eknoyan, 
1995, Giddings et al, 2009). His work unfortunately led to great 
misinterpretation in the scientific community at the time, where the treatment 
of cystic bone lesions found on early radiographs was to supplement patients 
with parathyroid extract, or transplanting bovine parathyroid tissue to 
alleviate the “gap” between hormone production and demand (Rogers-
Stevane and Kauffman, 2008). This misinterpretation was also enhanced by 
the widely accepted detoxification theory of the parathyroid glands at that 
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time. In 1925, James B Collip, a renowned Canadian biochemist successfully 
patented an extract of parathyroid hormone (PTH) from crushed ox 
parathyroid glands, and ‘Collip’s [parathyroid] extract’ was mistakenly 
known to be the mainstay treatment for osteitis fibrosa cystica (Eknoyan, 
1995, Thompson, 1990).  Collip was also the first to induce experimental 
hypercalcaemia and to describe the effects of severe hypercalcaemia 
(Thompson, 1990). 
 
Felix Mandl (Figure 4), a Viennese surgeon and protégé of von Eiselberg, is 
acclaimed to be the first parathyroid surgeon. In 1925, he pioneered multiple 
surgeries seeking a parathyroid tumour, and excising it from the neck of a 
patient (Delbridge and Palazzo, 2007, Giddings et al, 2009, Rolleston, 
1936). The patient’s name was Mr Albert Gahne, who was a 34 year old tram 
car conductor whose symptoms dated back to 1921. He initially presented to 
von Eiselberg’s clinic with hip and lower extremity pain. Mandl was 
involved in the patients’ care and on x ray, diagnosed the patient as 
having osteitis fibrosa cystica. His blood and urinary calcium levels were 
found to be elevated, with an observed white urinary precipitate (Dolev, 
1987). Initially, Mandl unsuccessfully treated Gahne’s condition by 
administering thyroid extract, Collip’s extract, and even attempted placing 
parathyroid graft from a donor victim of a road accident. Mandl then decided 
to explore the patient’s neck and resected an enlarged parathyroid gland 
(25×15×12mm) with excellent bone recovery, normalisation of serum 
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calcium and decreased urinary calcium excretion (Rogers-Stevane and 
Kauffman, 2008). However, the patient developed recurrent disease and in 
1933, Mandl re-operated on Mr Gahne’s neck, and found two normal 
parathyroid glands, one of which was intra-thyroidal. A subtotal 
thyroidectomy was performed as he considered an intrathyroidal adenoma as 
a possibility; however the patient died three years later without 
postoperative tetany (Giddings et al, 2009). Given that the post-mortem did 
not identify any parathyroid tissue or tumour, it is suggested that the patient 
may have deceased from parathyroid carcinoma with occult metastasis 
(Carney, 1996).  
 
Figure 4. Felix Mandl (1892-1957) was Professor of Surgery and Chairman 
of the Department of Surgery at Franz-Joseph-Spital, Vienna, Austria (Roher 
and Schulte, 2007) 
 
However, Delbridge and Palazzo (2007) considered that Sir John Bland-
Sutton, President of the Royal College of Surgeons of England, UK 1923 had 
performed the first intentional removal of a parathyroid tumour before 1917, 
almost a decade before Mandl. Bland-Sutton was a pre-eminent surgical 
pathologist of his time. He had extensive experience of parathyroids where 
he described a post-mortem specimen of a parathyroid tumour in 1886 and 
surgically removed a parathyroid cyst in 1909 (Delbridge and Palazzo, 
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2007). In Bland-Sutton’s sixth edition (1917) of the textbook Tumours: 
Innocent and Malignant, he recounts one of his patients:  
 
‘…a young married woman…was on a ship in the Red Sea and had great 
difficulty in breathing; a small rounded lump was detected in her neck below 
the thyroid gland. It increased in size and the dyspnoea became so urgent 
that one night the patient was prepared for tracheostomy and the ship’s 
surgeon remained by the bedside with instruments. Fortunately, the swelling 
subsided. On her return to England, I removed the rounded body, as big as a 
cherry, situated below the lower angle of the thyroid gland on the left side of 
the trachea. It had the microscopic features of a parathyroid’ (Bland-Sutton, 
1917).   
 
The report could be consistent with a haemorrhage into a parathyroid 
adenoma. It is unclear whether the presentation in this case was of 
mechanical effects of the parathyroid adenoma with local pressure, or 
whether the patient suffered symptoms associated with a hypercalcaemic 
crisis given that the removed tumour was only the size of a cherry (Delbridge 
and Palazzo, 2007). However, given the paucity of knowledge regarding 
associations of calcium, bone disease and parathyroid gland during this time, 
Mandl must still be credited for carrying out his operation with a curative 
intent on removing an abnormal parathyroid gland (Delbridge and Palazzo, 
2007). 
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Cervical explorations for pathological parathyroid glands became 
increasingly popular and refined after Mandl, however surgeons were 
grappling with the possibility and difficulty of ectopic parathyroid glands. 
Captain Charles Martell (Figure 5a), a 30 year old male of New York City 
was a healthy marine sea captain until three years before admission, when 
generalized skeletal decalcification set in (Dolev, 1987). He was investigated 
at the Massachusetts General Hospital (MGH) to have serum calcium and 
phosphorus levels of 14.8mg/dL and 3.3mg/dL respectively. A diagnosis of 
primary hyperparathyroidism was confirmed and in May 1927, Captain 
Martell underwent the first two operations by EP Richardson (Chief of 
Surgery, MGH) through a collar incision; the right neck was explored 
without finding an adenoma. A single normal parathyroid gland was 
removed. The second operation was limited to the left side, only one normal 
parathyroid gland was found (Dolev, 1987). In 1929, Captain Martell was re-
hospitalized where he underwent a third failed neck exploration. 
Unfortunately, his symptomatology was increasing, and renal function was 
deteriorating. He was readmitted to MGH in 1932, where he was studied 
extensively for 18 months in two metabolic wards. During this period, Oliver 
Cope (Figure 5b), under the direction of Edward Churchill (Figure 5c) (new 
Chief of Surgery, MGH) carried out a series of parathyroid gland dissections 
in cadavers in preparation for Martell’s re-operation. Cope had a reputation 
of performing several successful parathyroidectomies in early 1932 (Dolev, 
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1987). During the latter half of 1932, Cope (who was assisted by Churchill) 
performed three additional negative cervical explorations. Meanwhile, 
Captain Martell read extensively in the Harvard Medical Library about the 
various locations of parathyroid glands. He found in the December 1931 
issue of Acta Medica Scandinavica that described a mediastinal parathyroid 
adenoma, and managed to convince Cope and Churchill to explore his 
mediastinum. In Martell’s seventh operation, a 3.0 cm mediastinal adenoma 
was found (Rogers-Stevane and Kauffman, 2008, Ellis, 1983).  Churchill and 
Cope excised only 90% of the adenoma, attaching the remnant with its 
vascular pedicle to tissue in the region of the external notch. Despite these 
precautions, tetany developed on the third postoperative day (Dolev, 1987). 
Six weeks after the operation, a ureteric calculus became impacted. Captain 
Martell died from laryngospasm shortly after surgery to relieve obstruction 
from his stone. Few patients in the annals of history have been studied as 
extensively as Captain Martell (Dolev, 1987). 
 
Figure 5. Top left and right: Captain Charles Martell; Bottom left: Oliver 
Cope; Bottom right: Edward Churchill (Roher and Schulte, 2007) 
 
Benjamin Castleman (MGH) and others began to document gradually larger 
series of PTX in the 1930s, and the realization that the pathology of primary 
hyperparathyroidism was associated with not only solitary adenoma, but also 
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double adenomas and multi-glandular hyperplasia was soon recognized 
(DuBose and Morvant, 2005). Thus, bilateral neck explorations proved to be 
a commonly used procedure until more minimally invasive procedures began 
to gain acceptance in the 1980s.  
 
Pappenheimer and Wilens in 1935 were one of first authors to report that 
parathyroid glands from patients with chronic nephritis were significantly 
larger than glands from normal individuals, due to ‘some common chemical 
factor that stimulates the parathyroids to increased activity and growth’ 
(Pappenheimer and Wilens, 1935). They concluded that the cases involving 
severe nephritis were characterized by phosphate retention, which would 
result in a reduction in ionized calcium (as determined by Collip). This may 
incite the parathyroid glands to secrete more parathyroid hormone and grow 
in size (Pappenheimer and Wilens, 1935). At about this time, William Kloff, 
a Dutch physician, considered the Father of Dialysis, construct the first renal 
dialyzer after helplessly watching a young man die slowly of renal failure at 
the University of Groningen Hospital, Netherlands in the late 1930s (Davita, 
2017).  He was inspired by a report from a pharmacologist, John Abel in 
1913, from the Johns Hopkins University, who reported on haemodialysis in 
animals (Davita, 2017). In 1943, Kloff constructed his first haemodialysis 
machine with sausage skins, orange juice cans, and used auto parts, and 
treated 16 patients with acute renal failure, initially with little success 
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(Davita, 2017). After continued improvisation, he was able to regain 
consciousness of a 67 year old woman in uraemic coma using Kloff’s 
dializer (Davita, 2017). Her first words were reportedly “I’m going to 
divorce my husband!” (Davita, 2017). This paved way for new 
understanding of renal hyperparathyroidism, as patients with end stage renal 
failure survived longer with dialysis, and developed more florid secondary 
hyperparathyroidism. 
 
After the initial findings of Collip’s extract, laboratory measurements for 
PTH were extremely unreliable, hampering its applicability. It took another 
40 years before the discovery of a more effective method for the 
measurement of PTH and other peptides by Berson and Yalow, giving rise to 
more precise evaluation of such patients (Toneto et al, 2016). They 
developed a radio-immunoassay analytical test, which won them a Nobel 
Prize in 1977 (Nobelprize.org, 1977). The improvement in the determination 
of serum calcium and PTH yielded an improvement in the understanding of 
metabolic bone and calcium related  disorders. The number of patients 
diagnosed with hyperparathyroidism, even asymptomatic, increased 
considerably, making it possible to uncover the various clinical and 
metabolic aspects related to diseases of the parathyroid glands (Toneto et al, 
2016). Berson and Yarlow’s discovery facilitated a significant increase in 
parathyroid operations during the 1980s. 
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In 1982, Tibblin et al proposed unilateral neck exploration and 
parathyroidectomy for primary hyperparathyroidism as an acceptable 
alternative, provided that the normal ipsilateral gland could be identified 
(DuBose and Morvant, 2005, Tibblin et al, 1982). Better preoperative and 
intraoperative localization studies supported the use of this surgical option 
and even less invasive procedures in some situations (DuBose and Morvant, 
2005). In 1989, AJ Coakely noticed that technetium sestamibi was rapidly 
taken up by the parathyroid glands, thus provided surgery with a potent tool 
for preoperative imaging, useful in both initial and redo surgeries (Coakley et 
al, 1989). In 1988, Nussbaum provided evidence that PTH could be 
measured rapidly during the operation and thereby confirming success, hence 
rendering intraoperative frozen section much less important (Nussbaum et al, 
1998). Different combinations of imaging techniques and intraoperative 
hormone assessments are still under consideration with regard to 
successfully localizing glands, and increasing cost efficiency. The use of 
endoscopic parathyroidectomy for parathyroid disease of the mediastinum by 
Prinz et al at Rush University Medical Centre, and in the neck by Gagner at 
Columbia in the mid-1990s has introduced exciting additional surgical 
options for consideration (Prinz et al, 1994, Gagner, 1996). 
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In summary, the history of parathyroid glands and parathyroidectomy is one 
that has initially confused and misled clinicians and patients over the last 180 
years. Its understanding of diseases has developed through chance, trial and 
error, case reports and laboratory research. Contributors have come from 
various fields of science, and have made important contributions at various 
stages of their training. There is great debt to the early sufferers of 
parathyroid diseases for their help in advancing our understanding. It is 
prudent to remember the evolution that has already occurred, even as 
medicine continues to write new chapters in the history of parathyroid 
surgery. 
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Chapter 2: Embryology, Anatomy and 
Histology of Parathyroid Glands 
 
2.1 Embryology 
The parathyroid glands develop from the pharyngeal pouches, which are 
temporary endodermal out-pockets that also form the thymus and ultimo-
branchial bodies in vertebrates. The pharyngeal apparatus consists of the 
pharyngeal arches, pouches, grooves and the membranes. These early 
embryonic structures contribute to organogenesis of the head and neck 
structures.  
 The pharyngeal arches begin to develop early in the fourth week of 
gestation, as neural crest cells migrate into the future head and neck regions. 
Each pharyngeal arch consists of a core of mesenchyme and is covered 
externally by ectoderm, and internally by endoderm (Moore et al, 2013). 
There are five pharyngeal arches (of which the fifth pharyngeal arch 
is rudimentary), each separated by a pharyngeal groove and they contribute 
extensively to the development of the face, nasal cavities, mouth, larynx, 
pharynx and neck (Moore et al, 2013).   
The endoderm of the pharynx (that lines the internal aspects of the 
pharyngeal arches) passes into pharyngeal pouches, which develop in 
a cranio-caudal sequence between the arches (Moore et al, 2013). The 
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pharyngeal membranes are double layered, and derived from the endoderm 
of pouches which contacts the ectoderm of the pharyngeal grooves. There are 
four defined pairs of pharyngeal pouches in humans (fifth pair is 
rudimentary), each which gives rise to important organs of the head and 
neck.   
 
The development of the parathyroid glands can be thought of as being 
intimately connected with that of the thymus (particularly the inferior 
parathyroid glands), as it is often found by the occurrence of the parathyroid 
gland(s) embedded on the surface of the thymus, or buried within its 
substance (Gilmour and Grocers, 1937). They originate from the third 
(inferior parathyroid glands) and fourth (superior parathyroid glands) 
pharyngeal pouches that also form the thymus and ultimo-branchial bodies in 
vertebrates (Figure 6).  
 
Figure 6. Schematic of the branchial pouch and arches. The superior 
parathyroid glands originate from the fourth branchial pouch along with the 
ultimobranchial body that will contribute to the development of the thyroid 
gland. The inferior parathyroid glands originate from the third branchial 
pouch along with the thymus (Policeni et al, 2012). 
 
Nearly all of the information regarding parathyroid organogenesis has come 
from studies in mice, facilitated by the identification of the early regulation 
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of parathyroid differentiation genes, glial cells missing 2, or Gcm2 (Manley, 
2015, Kim et al, 1998). The expression of Gcm2 throughout parathyroid 
organogenesis allowed the tracking of parathyroid fated cells during 
embryonic development and has been a key to the recent developments in 
understanding parathyroid organogenesis (Manley, 2015, Kim et al, 1998). 
As development proceeds, genes involved in calcium homeostasis, such as 
parathyroid hormone (PTH), and calcium sensing receptor (CasR) are 
upregulated in the developing parathyroid, and with Gcm2, remain 
transcribed in the parathyroid rudiments as they migrate towards the midline 
and into adulthood (Liu and Manley, 2007).   
 
The third pharyngeal pouch expands and develops a solid, dorsal bulbar part 
and a hollow, elongate ventral part. By the sixth week of gestation, the 
epithelium of each dorsal bulbar part of the pouch begins to differentiate into 
an inferior parathyroid gland, whilst the epithelium of the elongate ventral 
parts of the pouch proliferates, to form the thymus (Moore et al, 2013). The 
thymus and parathyroid glands both usually lose their connections to the 
pharynx at seven weeks gestation (Zapanta and Meyers, 2016). The thymus 
migrates caudally and medially, pulling the inferior parathyroid glands with 
it, therefore they are positioned in a more inferior position than are 
parathyroid glands derived from the fourth pharyngeal pouch (Zapanta and 
Meyers, 2016). Later, the parathyroid glands separate from the thymus to lie 
on the dorsal surface of the thyroid gland, usually outside of the fibrous 
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capsule of the gland itself. This close relationship between the inferior 
parathyroid glands and the thymus explains the variable position of the 
inferior parathyroid glands, as the thymus has a long course of descent into 
the superior mediastinum, and frequently presents in ectopic locations 
(Policeni et al, 2012) (see section on anatomy of parathyroid glands). The 
fibroblast growth factor signalling pathways, acting through FRS2-α are 
thought to be implicated in the development of the thymus and parathyroid 
glands (Moore, 2013, Manley, 2015, Grevellec and Tucker, 2010).   
 
The superior parathyroid glands originate from the fourth pharyngeal pouch. 
The fourth pharyngeal pouch expands into dorsal bulbar and elongate ventral 
parts, and its connection with the pharynx is reduced to a narrow duct that 
soon degenerates (Moore et al, 2013). The superior parathyroids start 
developing from the dorsal part and migrate caudally during the fifth and 
sixth weeks of gestation (Policeni et al, 2012, Moore and Persaud, 1998, 
Safford and Skinner, 2006). At gestational week seven, the glands lose 
connections with the pharynx and attach themselves to the thyroid gland, 
which is also migrating caudally. The superior parathyroids are generally 
located more posterior and medial than the inferior parathyroid glands, and 
their final resting point is usually on the dorsal surface of the thyroid gland, 
outside the fibrous capsule of the thyroid gland (Zapanta and Meyers, 
2016).   
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2.2 Anatomy  
The parathyroid glands are small flattened, oval/kidney bean 
shaped bodies which usually lie on the medial half of the posterior surface of 
each lobe of the thyroid gland, where they may be either within, or outside 
the thyroid capsule of pre-tracheal fascia (Moore et al, 2010, McMinn, 
2011). Most humans have four parathyroid glands (two superior, two 
inferior), although this can range from two to six glands (supernumerary), 
with some authors reporting up to twelve glands (Som and Curtin, 2003, 
O’Rahilly and Muller ,1996) (Figure 7). In one series, more than four glands 
were found in 13% of the cases, four glands in 84% and three glands in 3% 
of the cases (Akerstrom et al, 1984). The percentage of individuals with less 
or more than four glands may be difficult to report as the researcher may 
have been unsuccessful in finding one or more glands, and a missed gland 
could represent an unobserved rather than an absent gland (Herrera and 
Gamboa-Dominguez, 2005).  
 
Figure 7. Posterior view of the pharynx, oesophagus and thyroid glands to 
visualize superior and inferior parathyroid glands (Mohebati and Saha, 2012) 
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The colour of normal parathyroid glands varies depending on the age of the 
patient, extracellular fat content, the degree of vascular congestion, and the 
number of oxyphil cells present. In the newborn, they are grey and 
semitransparent. They are light pink in children, turning yellow in adults as 
their fat content increases. In older adults, they become darker (Herrera and 
Gamboa-Dominguez, 2005). The parathyroid glands may conceivably be 
confused with small lobules of adipose tissue, with accessory nodules of the 
thyroid gland, or even with lymph nodes (Greenson et al, 2015). Normal 
glands are usually the size of a grain of rice or lentil, between 2 and 7mm in 
length, 2 and 4mm in width, and 0.5 to 2mm in thickness. The combined 
weights of all parathyroid glands in a healthy male averages about 120mg, 
and in an adult female around 145mg. Weights of individual glands range 
from 30 to 75mg, with reported averages of 35 to 55mg (Greenson et al, 
2015).   
 
The superior gland originates from the fourth branchial pouch, and as 
parathyroid glands lose their attachment with the pharyngeal wall, they 
attach to the posterior mid surface of the caudally migrating thyroid, near the 
tracheal-oesophageal groove (Mohebati and Saha, 2012). It has a shorter 
embryologic descent than their inferior counterparts, which leads to a smaller 
variability in location (Figure 8). In 85% of cases, the superior parathyroid 
can be found at the posterior aspect of the thyroid lobe in a two centimetre 
area centred one to two centimetres cranial to the crossing of the inferior 
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thyroid artery and the recurrent laryngeal nerve (Fancy et al, 2010, 
Randolph, 2003). Where the recurrent laryngeal nerve enters the point of 
Ligament of Berry and behind the cricoid cartilage, the superior glands may 
be found within 1cm.  They are usually at the level with the first tracheal 
ring, and lie under the thyroid superficial fascia, posterior to the recurrent 
laryngeal nerve. They may also reside inside the thyroid capsule, just 
superior and medial to the posterior tubercle of Zuckerkandl of the thyroid 
(Richards et al, 2015). In an autopsy series of 503 cases, 2% of ectopic 
superior parathyroid glands were found at the level of superior pole of the 
thyroid, and less than 1% were superior to it (Akerstrom et al, 1984, Fancy et 
al, 2010). They may also be placed further down, sometimes obscured by the 
inferior thyroid artery and the recurrent laryngeal nerve. Rarely, they are 
found in the retro-pharyngeal space, retro-oesophageal space and intra-
thyroidal (Herrera and Gamboa-Dominguez, 2005).   
 
Figure 8. Variations in the position of the superior and inferior parathyroid 
glands (Herrera and Gamboa-Dominguez, 2005) 
 
The inferior parathyroid glands have a more variable location due to their 
embryologic relationship to the thymus, which are both derived from the 
third branchial pouch (Policeni et al, 2012) (Figure 8). In 50% of cases, they 
are found within one centimetre inferior, lateral or posterior to the lower pole 
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of the thyroid, and are typically anterior to a plane drawn along the course of 
the recurrent laryngeal nerve and the superior parathyroid glands (Fancy et 
al, 2010, Randolph, 2003). However, ectopic inferior glands can be found 
anywhere along a large area of descent from the angle of the mandible to the 
superior border of the pericardium and the aorto-pulmonary window (Gray et 
al, 1976) (Figure 9). In a study of 645 parathyroid glands from 160 cases, 
42% of the inferior parathyroid glands were found on the inferior or 
the postero-lateral surface of the lower pole of the thyroid, 39% were located 
in the lower neck in proximity to the thymus and thyro-thymic ligament, 
15% lateral to the thyroid, and only 2% within the mediastinal thymic tissue 
(Mohebati and Shaha, 2012, Wang, 1976). In rare cases (2.8%), the inferior 
gland can be found superior to the intersection of the recurrent laryngeal 
nerve and the inferior thyroid artery, intra-thyroidal (3%) and within the 
carotid sheath (2%) (Herrera and Gamboa-Dominguez, 2005, Fancy et al, 
2010). If there has been a failure of inferior gland descent during its 
embryological development, they may be found high in the neck and even 
above the upper pole of the thyroid; however these glands are usually 
surrounded by a remnant of thymic tissue (Herrera and Gamboa-Dominguez, 
2005).   
 
Figure 9. A-C: Coronal, sagittal and transverse Computed Tomography (CT) 
scan of head and neck and superior mediastinum, demonstrating enhancing 
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mass in superior mediastinum, just anterior to the aorta and posterior to the 
sternum. D: Tc-99m sestamibi scan demonstrating persistent uptake of 
superior mediastinum mass  at 15(left) and 90 minutes (right) delay, 
consistent with a parathyroid adenoma (Policeni et al, 2012). 
In the majority of cases, parathyroid glands are located in symmetrical 
position in the neck. There have been reports of symmetry at 80% for the 
superior and 70% for the inferior glands, with a relative symmetry of 60% 
for all four glands (Akerstron et al, 1984, Mohebati and Shaha, 2012, Fancy 
et al, 2010). Thus, when unable to locate a missing parathyroid, contralateral 
neck exploration for comparison may be useful.   
 
Supernumerary parathyroid glands are known to occur in 2.5-15% of cases 
of which the majority are small, rudimentary or divided (Akerstrom et al, 
1984, Carter et al, 1993). They may be found anywhere along the line of 
thymic tissue descent during embryological development, however in two 
thirds of cases, they are found within the thymus or in relation to thyro-
thymic ligament. These glands may be responsible for persistent 
hyperparathyroidism after parathyroid surgery, especially in secondary and 
tertiary hyperparathyroidism, and in familial syndromes (Richards et al, 
2015).   
 
The blood supply of both upper and lower parathyroid glands is usually 
supplied by the inferior thyroid artery, with minute veins joining thyroid 
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vessels (McMinn, 2011). Each gland usually has its own end-artery. In 
particular, the superior parathyroid glands receive 80% of their arterial blood 
supply from this artery, 15% by the superior thyroid artery (most commonly 
via the posterior branch) and 5% via anastomoses running between the two 
systems (Herrera and Gamboa-Dominguez, 2005). On the other hand, 10% 
of the inferior parathyroid glands are vascularized by the superior thyroid 
artery, via anastomoses of both systems, or Neubauer’s artery (Herrera and 
Gamboa-Dominguez, 2005, Flament et al, 1982). Ligation of the branches of 
the inferior thyroid artery close to the thyroid parenchyma and medial to the 
recurrent laryngeal nerve may help preserve intact parathyroid vascularity 
during thyroid surgery (Richards et al, 2015). The venous drainage of the 
parathyroid glands are tributaries of the superior, middle and inferior thyroid 
veins that drain into the internal jugular vein or the innominate vein.   
 
The lymphatic drainage of the glands are as for the thyroid gland and the 
thymus, which parallels the venous drainage. Lymph that follow superior and 
middle thyroid veins drain into the upper deep nodes of the cervical chain, 
and those accompanying the inferior vessels drain to the lower nodes of the 
cervical plexus, supraclavicular, paratracheal and parapharyngeal nodes 
(Mohebati and Shaha, 2012, Hoyes and Kershaw, 1985).  
 
The nerve supply of the parathyroid glands is abundant; it is derived from 
thyroid branches of the cervical sympathetic ganglia, which enter the 
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parathyroid parenchyma with the arteries. Like the nerves to the thyroid, they 
are vasomotor rather than secreto-motor because the glands are hormonally 
regulated (Moore et al, 2010). 
 
Ultimately, the surgical implication is that appreciation and sound 
understanding of the embryology and anatomy of the parathyroid glands 
assist surgeons to better locate and visualize the glands, decreasing the 
incidence of missing an abnormal/ectopically located/supernumerary 
gland(s), conditions leading to persistence of disease. 
 
2.3 Histology  
2.3.1. Normal parathyroid gland 
The parathyroid gland is enclosed within a thin connective tissue capsule 
(Figure 10). Thin septa of loose connective tissue extend inwards and merge 
with the delicate framework of reticular fibres, carrying the 
blood vessels, vasomotor nerves and lymphatics (Junquiera et al, 
1998). However, the septa do not divide the gland into distinct lobules (Ham 
and Cormack, 1989). From these septa, epithelial cells may rarely form 
isolated small follicles resembling the thyroid gland, containing colloid 
material bearing no functional relationship to the colloid of the thyroid gland. 
The connective tissue stroma of the gland, in normal adults, contains a 
variable number of adipose cells. Historically, the cell to fat ratio of 50:50 
has been accepted as normal for adults, although in the elderly, the fat may 
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occupy as much as 60% of the gland (Greenson et al, 2015, Fawchett and 
Jensh, 2002). However, the overall weight of the parathyroid glands 
normally remains constant during adult life, thus there is an age-related 
decrease in the mass of chief cells (Kacsoh, 2000).   
The parenchyma of the human parathyroid gland consists of three cell types: 
the chief (or principal) cells, the oxyphil cells and transitional cells. The 
latter cell’s function however, is still yet to be elucidated (Junquiera et al, 
1998) (Figure 10).   
 
Figure 10. Haematoxylin and eosin stain photomicrograph of human 
parathyroid gland. The connective tissue capsule (Cap) surrounds the gland 
with blood vessels (BV) located within the septum separating the lobes of the 
parathyroid gland. The principal cells are separated by oxyphil cells. Adipose 
tissue (AC) become more abundant with age (Ross and Pawlina, 2006) 
 
Chief cells are small, polygonal cells with a diameter of 4 to 8 micrometres 
and a centrally located nucleus. They are the more numerous of the cell type, 
responsible for the secretion of PTH. Sometimes, they are divided into clear 
and dark forms, depending on the amount of granules in its cytoplasm. Its’ 
cytoplasm is lightly eosinophilc, containing lipofuscin-containing vesicles, 
large accumulations of glycogen and lipid droplets (Ross and Pawlina, 
2006). On electron microscope, they are found to be joined by occasional 
desmosomes (Fawchett and Jensh, 2002). In contrast to other glands, in 
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which all cells normally exhibit the same degree of activity, parathyroid 
chief cells appear to go through their secretory cycle independently. 
Amongst the active cells, they are seen to contain long mitochondria, parallel 
cisternae or rough endoplasmic reticulum, a prominent Golgi complex and 
small deposits of glycogen. Within the cytoplasm, small, dense, membrane-
limited vesicles containing irregularly shaped granules 200-400 nanometre in 
diameter are thought to be the storage form of PTH (Junquiera et al, 1998, 
Ross and Pawlina, 2006). These granules are distributed throughout the 
cytoplasm; sometimes they are more numerous at the vascular pole of the 
cell (Junquiera et al, 1998).   
 
On the other hand, oxyphil cells constitute a minor portion of the 
parenchymal cells, and are not known to have a secretory role. The precise 
functions of these cells are still uncertain. They begin to appear from about 
age 5-7, and increase in number with age, with some suggestion that they 
probably arise from chief cells previously present (Junquiera et al, 1998, 
Ham and Cormack, 1989).  They are found singly or in clusters; the cells are 
more rounded, considerably larger (6-10micrometer in diameter) than chief 
cells, and have a distinctly acidophilic cytoplasm, which is granular (Ross 
and Pawlina, 2006, Leeson et al, 1985). They have small, darkly staining 
nuclei (Leeson et al, 1985). Their Golgi complex is small, the cytoplasmic 
reticulum is sparse, and there are no secretory granules. They have an 
unusually large number of mitochondria and have closely spaced cristae, 
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suggesting a high degree of metabolic activity (Fawchett and Jensh, 2002). 
Cytoplasmic inclusion bodies consist of occasional lysosomes, lipid droplets 
and glycogen distributed among the mitochondria (Ross and Pawlina, 
2006).   
 
Finally, the transitional cell is thought to have cytological characteristics 
intermediate between those of the chief cell and the oxyphil cell (Bloom and 
Fawcett, 1997). It stains with acid dyes and has a nucleus that is somewhat 
similar and more deeply staining than that of the other cell types. Because 
only one hormone is produced by the parathyroid glands, the above three cell 
forms are widely thought to be different phases in the life cycle of a single 
cell type, with the chief cell being its physiologically active stage (Bloom 
and Fawcett, 1997). This interpretation is supported by immunological 
studies localizing radioactive precursors of the hormone mainly over the 
secretory granules of the chief cells (Bloom and Fawcett, 1997). 
 
2.3.2: Parathyroid glands in end stage renal failure  
The vast majority of parathyroid gland abnormality in end stage renal failure 
is adaptive parathyroid hyperplasia, defined as an absolute increase in the 
mass of the parenchymal cells of the parathyroid gland.  Most cases are chief 
cell hyperplasia. Usually, all four glands are involved, weighing on average, 
a total of 1-3 grams (Pathology Outlines, 2017). In advanced hyperplasia, 
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variations in gland size may be considerable, and the glands may exhibit 
considerable fibrosis, cyst formation and calcification (Fawchett and Jensh, 
2002) (Figure 11).  
 
Figure 11. Cross sections of parathyroid glands demonstrating variations in 
sizes, colour and nodularity. R: Right parathyroid glands; L: Left parathyroid 
glands (Fawchett and Jensh, 2002, Roth, 1997).  
 
The earliest change in the parathyroid glands is a reduction in the quantity of 
fat cells in the intervening stroma, and their partial replacement by 
vacuolated chief cells, arranged in either diffuse sheets, cord-like, acinai or 
trabecular growth patterns (Fawchett and Jensh, 2002, Greenson et al, 2015). 
Their nucleus is small and dense, and occupies an eccentric position within 
the cytoplasm (Fawchett and Jensh, 2002). Vacuolated chief cells are 
typically rich in glycogen, with little neutral lipid.  Ultra structurally, they 
have fairly straight plasma membranes with few desmosomal attachment 
sites (Fawchett and Jensh, 2002). Their cytoplasm contain numerous 
secretory granules, adjacent to Golgi regions or plasma membranes 
(Fawchett and Jensh, 2002). Oxyphil cells are usually fewer in number 
(Greenson et al, 2015). Nodule formation is common in advanced renal 
hyperparathyroidism composed mainly of chief cells, which may be 
surrounded by fibrosis and for some, entirely encapsulated (Greenson et al, 
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2015, Lawrence, 1978) (Figure 12). A rim of normal parathyroid tissue is 
not typically present, as is used as a criterion for the diagnosis of adenoma 
(Lawrence, 1978). 
 
Figure 12. Multiple nodules can be seen surrounded by fibrosis in secondary 
hyperparathyroidism, with adjacent parathyroid tissue diffusely hyperplastic 
(Greenson et al, 2015) 
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Chapter 3: Parathyroid Gland Physiology 
and Calcium Homeostasis 
The hormones involved with calcium homeostasis include (1) parathyroid 
hormone (PTH), a protein secreted by the parathyroid glands (2) Vitamin D- 
1, 25 dihydroxycholecalciferol (1, 25 DOHCC), a steroid; (3) calcitonin, a 
protein produced and released by the para-follicular cells of the thyroid 
gland; (4) parathyroid hormone related protein (PTHrP), particularly in 
paraneoplastic syndromes and (5) gonadal steroids (estrogens and/or 
testosterone) (Moffett et al, 1993).  
 
3.1 Parathyroid Hormone  
The PTH gene possesses upstream regulatory elements in the 5’ region, 
including both vitamin-D and vitamin-A response elements. The vitamin-D 
response elements bind a vitamin D receptor (VDR), when the receptor is 
occupied by a vitamin D metabolite, usually 1, 25 DOHCC (Boron and 
Boulpael, 2012). The receptor has a very high affinity for 1, 25 DOHCC, less 
affinity for the 25-hydroxy form, and little affinity for the parent vitamin 
(either vitamin D2 or D3). Binding of the vitamin D-VDR complex to the 
VDR response element reduces the rate of PTH transcription (Boron and 
Boulpael, 2012). PTH is initially synthesized in the chief cells as a larger 
molecular weight precursor called pre-pro-parathyroid hormone (115 amino 
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acids). This then enters the endoplasmic reticulum, whereby a leader 
sequence is removed from the amino terminal to form the 90-amino acid 
polypeptide pro-PTH (Glasby and Huang, 1995). Six further amino acids are 
then cleaved before secretion from the secretory granules, such that the 
parathyroid hormone itself contains only 84 amino acids (Glasby and Huang, 
1995) (Figure 13). Once secreted, PTH circulates free in blood plasma, and 
is rapidly metabolized; the half-life being approximately 4 minutes. Next, the 
circulating PTH is then cleaved into two principal fragments in the liver- a 
33- or 36-amino acid N terminal peptide, and a larger C terminal peptide, 
with virtually all of the known biologic activity of PTH residing in the N-
terminal fragment, which is rapidly hydrolysed, especially in the kidney 
(Boron and Boulpael, 2012). In the past, this cleavage made the 
interpretation of results of PTH assays confusing, since the N- terminal and 
C-terminal fragments cross-reacted in the PTH immunoassay. Newer assays 
now measures only the intact PTH hormone (i.e. 84 amino acids), and have 
allowed scientists to expand their understanding of PTH physiology (Glasby 
and Huang, 1995).   
 
Figure 13. Molecular pathway of PTH synthesis. The production of PTH 
initially begins with pre-pro-PTH (115 amino residues) in the rough 
endoplasmic reticulum, which is then cleaved to form a pro-PTH (90 
residues). In the Golgi apparatus, the pro sequence is cleaved by its enzymes 
to form PTH hormone stored in secretory granules (84 residues). This is then 
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further cleaved into two fragments, with the N terminal fragment (33-36 
amino residue) containing all of the biologic activity (Boron and Boulpael, 
2012) 
 
PTH release is controlled in a tight feedback system by small changes in 
plasma calcium levels detected by the parathyroid calcium-sensing receptor 
(CaRs), a G protein-coupled receptor located on the plasma membrane of the 
parathyroid chief cells; it is also found in kidney tubule cells and thyroid C 
cells (Raff and Levitzky, 2011). This receptor binds calcium in a saturable 
manner, with an affinity profile that is similar to the concentration 
dependence for PTH secretion (Boron and Boulpael, 2012). Coupling 
of CaRs to Gαq activates phospholipase C, thus generating inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG) and resulting in the release of 
calcium from internal stores and the activation of protein kinase C (Boron 
and Boulpel, 2012). However, unlike most G protein coupled receptors in 
which activation of these signalling systems promotes a secretory response, 
an inverse relationship between the concentration of ionized calcium in the 
extracellular fluid and PTH secretion by the chief cells exists, which is 
steeply sigmoidal. This means that a minor decrease in extracellular calcium 
leads to a marked increase in PTH secretion within seconds (Raff and 
Levitzky, 2011, Kacsoh, 2000). The inflection point of the negative sigmoid 
curve is found at an extracellular calcium slightly lower than the normal 
plasma value. Thus, under resting conditions, PTH is secreted at rates of only 
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2-25% of the maximal output (Kacsoh, 2000). In the chief cell, stimulus 
secretion coupling is performed by intracellular magnesium, rather than by 
calcium. Thus, depletion of magnesium stores can lead to 
hypoparathyroidism, as well as hyper-magnesemia can also inhibit PTH 
secretion due to its binding with the CaRs (Kacsoh, 2000).   
PTH increases reabsorption of calcium in the distal tubules, although 
calcium excretion in the urine is often increased in hyperparathyroidism 
because the increase in the load of filtered calcium overwhelms the effect on 
reabsorption (Barrett et al, 2012). PTH increases the phosphate excretion in 
the urine and thereby, depresses plasma phosphate levels (Barrett et al, 
2012). PTH also increases the formation of 1, 25 DOHCC by stimulating 1α 
hydroxylase activity in the proximal tubular cells of the kidney, and this 
further increases the calcium absorption from the intestine (Michael and 
Sircar, 2010). Finally, PTH acts directly on bone to increase bone resorption 
and mobilize calcium (Figure 14).  
 
Figure 14. The systemic effects of increased PTH from reduced plasma 
calcium concentration. PTH (along with synergistic effects with vitamin D) 
has effects on end organs (kidneys, bone, intestine) to counteract relative 
hypocalcaemia (Moffett et al, 1993). 
 
 A key action of PTH is to promote the reabsorption of calcium in the thick 
ascending limb (TAL) and distal convoluted tubule (DCT) of the kidney. 
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Most of the approximately 250 milli-moles of calcium filtered each day is 
reabsorbed in the proximal tubule (~65%) and TAL (~25%), with the distal 
nephron reabsorbing additional 5-10% of the filtered load of calcium (Boron 
and Boulpael, 2012). Thus, when PTH stimulates distal calcium 
reabsorption, it will greatly decrease the amount of calcium excreted in the 
urine. Vitamin D has a synergistic action of promoting calcium reabsorption 
in the DCT (Boron and Boulpael, 2012). Concurrently, PTH promotes 
phosphate excretion into the urine by inhibiting the reabsorption of 
phosphate in the proximal and distal tubule, resulting in 
phosphaturia and hypophosphatemia (Barrett et al, 2012, Boron and Boulpel, 
2012). This phosphaturia results from a PTH-induced redistribution of the 
Na/phosphate co-transporter (NaPi) away from the apical membrane of the 
renal proximal tubule, and into a pool of subapical vesicles for subsequent 
lysosomal degradation (Raff and Levitzky, 2011, Boron and Boulpael, 
2012). The elimination of phosphate is physiologically important, as PTH 
induced increase in plasma calcium, if accompanied by a rise in phosphate 
levels from degradation of bone, would cause phosphate salts to precipitate 
out of the soluble phase, at least partly negating the action of PTH to raise 
plasma calcium levels (Boron and Boulpael, 2012). Thus, the two functions 
of calcium retention and phosphate excretion tend to leave plasma [Ca2+]▪[Pi] 
unaltered (Kacsoh, 2000).   
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PTH has multiple actions on bone, some direct and others indirect, of which 
the changes mediated by PTH are observed within minutes. The chronic 
effects of PTH are to increase the number of bone cells, both osteoblasts and 
osteoclasts, and to increase the remodelling of bone- these effects are 
apparent within hours after the hormone is given and persist for hours after 
PTH is withdrawn (Kasper et al, 2005). Continuous exposure to elevated 
PTH (such as in renal hyperparathyroidism) leads to increased osteoclast-
mediated bone resorption. These processes are due to PTH binding onto 
receptors found in osteoblasts stimulating the activity of several proteins, 
including osteoclast-differentiating factor (ODF), also known as receptor 
activator of nuclear factor-κβ ligand (RANKL), or osteoprotegerin ligand 
(Raff and Levitzky, 2011). In addition, PTH stimulates osteoblast expression 
of genes involved in degradation of the extracellular matrix and bone 
remodelling (collagenase-3), production of growth factors (insulin like 
growth factor 1), and stimulation and recruitment of osteoclasts (RANKL 
and interleukin 6) (Raff and Levitzky, 2011).  
 
Interestingly to a much lesser extent, intermittent administration of PTH, 
elevating hormone levels for 1-2 hours each day, leads to a net stimulation of 
bone formation, rather than breakdown (Kasper et al, 2005).  In this pathway, 
PTH promotes bone synthesis directly by activating calcium channels from 
bone fluid to the osteocytes. The osteocytes then transfers the calcium via 
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gap junctions to the osteoblasts at the bone surface, a process called 
osteocytic osteolysis (Boron and Boulpael, 2012). The osteoblasts then pump 
the calcium into the extracellular matrix, thus contributing to mineralization. 
Also, PTH stimulates bone synthesis indirectly in that osteoclastic bone 
resorption leads to the release of growth factors such as insulin-like growth 
factor 1 (IGF-1), IGF 2 and transforming growth factor beta (Boron and 
Boupael, 2012).  
 
3.2 Vitamin D  
Vitamin D is a lipid soluble hormone. It acts like a group I 
(steroid) hormone, which interacts with nuclear receptors in target cells. 
However, it is also hydrophilic, as it contains three hydroxyl groups. Hence, 
it also acts like a group IIB hormone, acting through membrane receptors 
with cyclic guanosine monophosphate (cGMP) as the second messenger 
(Michael and Sircar, 2010).   
 
Vitamin D is provided as both vitamin D2 (plant sources) and vitamin 
D3 (meat and fish) in the diet. In addition, vitamin D3 can be formed by the 
action of light on pro-vitamin D3 (7-dehydrocholesterol) present on the skin. 
Endogenous synthesis of vitamin D3 is important since deficiency may arise 
through inadequate exposure to sunlight or inadequate oral intake (Glasby 
and Huang, 1995). Vitamin D2 and D3 are of identical potency in humans, 
and are collectively referred to as cholecalciferol (Moffett et al, 1993). 
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Cholecalciferol is transported to the liver bound to a specific α-globulin 
(vitamin D transport protein), where hydroxylation at the 25 position in the 
liver produces 25-hydroxycholecalciferol (25-HCC; calcidiol). The 25-
hydroxycholecalciferol is then further converted in the cells of the proximal 
tubules of the kidneys by the action of 1-hydroxylase to the more active 
metabolite, 1, 25-dihydroxycholecalciferol (1, 25-DHCC), which is also 
called calcitriol [6]. The kidneys also contains 24-hydroxylase, which can 
convert 25-HCC to 24, 25 dihydroxycholecalciferol (24, 25-DHCC) and a 26 
hydroxylase which coverts 25-HCC to 25, 26 dihydroxycholecalciferol (25, 
26-DHCC), although the significance of these other metabolites are 
unknown. Calcitriol is also produced in the placenta, in keratinocytes in the 
skin and in macrophages (Barrett et al, 2012). 
   
1, 25-DHCC (calcitriol) mediates its biologic effects by binding to a member 
of the nuclear receptor superfamily, the vitamin D receptor (VDR). This 
receptor belongs to the subfamily that includes the thyroid hormone 
receptors, the retinoid receptors, and the peroxisome proliferator-activated 
receptors (Kasper et al, 2005).  The VDR binds to target DNA sequences as a 
heterodimer with a retinoid X receptor, recruiting a series of coactivators that 
result in the induction of target gene expression (Kasper et al, 2005). The 
affinity of the VDR for calcitriol is approximately three times of magnitude 
higher than for the other vitamin D metabolites. Under normal physiologic 
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circumstances, these other metabolites do not appear to stimulate receptor-
dependent actions (Kasper et al, 2005).    
 
Vitamin D has multiple systemic effects on target organs (Figure 15). 
Vitamin D promotes intestinal absorption of calcium and phosphate, which 
contributes to increased bone mineralization. It serves its function by 
induction of synthesis of calcium channels, pumps and calcium binding 
proteins intracellularly. Calcium moves from the intestinal lumen to the 
blood by both paracellular and transcellular routes. In the paracellular route, 
which occurs throughout the small intestine, calcium moves passively from 
the lumen to the blood, which is not regulated by calcitriol (Boron and 
Boulpael, 2012). The transcellular route, which occurs only in the 
duodenum, involves three steps: (1) calcium enters the cell across the apical 
membrane by calcium channels and endocytosis (2) calcium binds to several 
high affinity bindings proteins intracellularly, most prominently calbindin (3) 
the enterocyte extrudes calcium across the basolateral membrane by means 
of both a calcium pump and an Na-Ca exchanger (Boron and Boulpael, 
2012). Calcitriol also appears to stimulate intestinal phosphate uptake via 
genomic upregulation of Na-phosphate symporter (Boron and Boulpael, 
2012).  
 
In the kidneys, calcitriol appears to stimulate reabsorption of calcium via 
increased TRPV5 expression in the distal convoluted tubules, with its effect 
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significantly enhanced with the synergistic effect with PTH (Barrett et al, 
2012). As with enterocytes, calbindin appears to be present in renal tubular 
cells and probably has a role in increasing calcium absorption (Michael and 
Sircar, 2010). Additionally, albeit a lesser role than PTH, calcitriol also 
appears to promote phosphate reabsorption in the proximal tubule.  
 
Figure 15. Vitamin D metabolism and physiological effects at target organs 
(Raff and Levitzky, 2011) 
  
The actions of vitamin D on bone are more complex, in that it promotes both 
bone deposition and bone resorption. This is due to both osteoblasts and 
osteoclast precursor cells holding VDRs. Additionally, activated osteoblasts 
secrete osteoclast stimulating factor, which induces the development of 
osteoclasts from their precursors (Michael and Sircar, 2010).  Indirectly, 
vitamin D provides for increased extracellular calcium from the intestine and 
kidneys to provide for mineralization of previously un-mineralized osteoid. 
However, the direct effect of vitamin D on bone is thought to mobilize 
calcium out of bone (Boron and Boulpael, 2012). In response to vitamin D, 
osteoblasts produce a number of proteins, including alkaline phosphatase, 
collagenase and plasminogen activator (Boron and Boulpael, 2012). 
However, vitamin D, like PTH also promotes the development of osteoclasts 
from precursor cells, thus the net effect in vitamin D in experiments using 
vitamin D deficient animals appears to mobilize calcium from bone into the 
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extracellular medium (Boron and Boulpael, 2012, Kacsoh, 2000). At the 
same time, the relative hypercalcaemia appeared to promote mineralization 
of previously un-mineralized osteoid- at the expense of bone resorption from 
other sites (Boron and Boulpael, 2012). 
   
Finally, vitamin D is able to provide direct negative feedback back to the 
parathyroid glands to control rises in serum calcium. It does so via the 
5’regulatory region of the PTH gene within chief cells of parathyroid glands, 
which has a VDR sequence (Boron and Boulpael, 2012). When vitamin D is 
occupied by the VDR complex, this element is able to reduce transcription of 
PTH product.  
 
3.3 Calcitonin  
Calcitonin is a small peptide hormone with a molecular weight of 3500, 
containing 32 amino acids produced by “clear” or C cells of the thyroid 
gland. They are derived from the neural crest cells of the fifth branchial 
pouch, which in humans, migrate into the evolving thyroid gland (Glasby 
and Huang, 1995). Calcitonin is synthesized in the secretory pathway by 
post-translational processing of a large pro-calcitonin (Boron and Boulpael, 
2012). It is stored in secretory vesicles within the C cells, whereby its 
exocytosis is stimulated by a rise of extracellular calcium above normal, and 
conversely lowering the extracellular calcium diminishes its secretion. Β 
adrenergic agonists, dopamine, estrogens, gastrin, cholecystokinin, glucagon 
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and secretin have also been implicated in stimulating calcitonin secretion, 
with gastrin being the most potent stimulus (Barrett et al, 2012). Thus, the 
plasma calcitonin is seen to be elevated in Zollinger-Ellison syndrome and in 
pernicious anaemia (Barrett et al, 2012).  However, neither surgical or radio-
thyroidectomy, (which eliminates calcitonin from the circulation), nor does 
rare calcitonin secreting tumour of the C cells, with frequent plasma 
calcitonin concentrations that are 50-100 times above normal significantly 
alters plasma calcium levels. This probably indicates that calcitonin probably 
does not play a major role in the physiologic regulation of plasma calcium in 
humans (Kacsoh, 2000). In any event, the actions of calcitonin are short 
lived, because it has a half-life of less than 10 minutes (Barrett et al, 2012).   
 
The cellular effects of calcitonin are mediated through G protein coupled 
receptors from the same receptor family as PTH and PTHrP receptor 
superfamily (Raff and Levitzky, 2011). They are found mainly in bone and 
kidneys. Within bone, the osteoclast, which lacks PTH receptors but with the 
presence of calcitonin receptors, appears to inhibit the resorptive activity of 
the osteoclast and slows the rate of bone turnover (Boron and Boupael, 
2012). In patients who are in the osteolytic stage of Paget’s disease, but not 
in healthy adults, the acute inhibition of osteoclastic activity by parenteral 
administration of calcitonin was accompanied by a decline in plasma 
concentration of calcium (Kacsoh, 2000). However, exogenous calcitonin 
lost its effectiveness, perhaps due to receptor downregulation (Kacsoh, 
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2000). In the kidneys, calcitonin causes a mild phosphaturia by inhibition of 
proximal tubule phosphate transport, mild natriuresis and calciuresis. 
However, these renal effects are believed to be of short duration, and do not 
appear to be important in the overall renal handling of calcium, phosphate or 
sodium (Boron and Boulpael, 2012). Calcitonin has been a useful 
pharmacologic agent to suppress bone resorption in Paget’s disease and 
osteoporosis, and in the treatment of hypercalcaemia of malignancy.   
 
3.4 Parathyroid Hormone Related Protein  
The paracrine factor Parathyroid Hormone Related Protein (PTHrP) is 
responsible for most instances of hypercalaemia of malignancy, a syndrome 
that resembles hyperparathyroidism (Kasper et al, 2005). It is manufactured 
in a wide variety of normal tissues, including brain, pancreas, heart, lung, 
mammary tissue, placenta, endothelial cells and smooth muscles. It is also 
commonly implicated in squamous cell cancers of lung, head and neck, renal 
and bladder carcinomas. PTHrP is a product of a single multi-exonic gene, 
which is organised similar to that of PTH, however its genes are completely 
separate to that from PTH. Due to alternative splicing, three translation 
products are synthesized, and eventually secreted (Kacsoh, 2000):  
 
 PTHrP (1-36) is homologous with PTH and acts on 
PTH/PTHrP receptor and N terminal PTHrP-specific receptor;  
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 Mid-region PTHrP [PTHrP (38-94), (94-95) and (38-101)] acts on its 
own unique receptor;  
 C-terminal PTHrP (107-139), termed osteostatin for its direct 
osteoclast inhibiting action, which involves a distinct receptor. 
 
The similar actions of PTHrP and PTH arise from homology within the first 
13 amino acids of PTHrP (as above) with native PTH, with only weak 
homology seen between amino acids 14-34 (3 amino acids are identical), and 
essentially no homology beyond amino acid 34 (Boron and Boulpael, 
2012).   
 
The normal physiologic functions of PTHrP are still largely unknown. In non 
lactating humans, the plasma PTHrP concentration is kept at very low levels, 
and does not appear to be involved in day to day regulation of serum calcium 
levels. It is thought to contribute to local stimulation of calcium transport, 
activation of renal 1α-hydroxylase activity in the kidney, and 
provide local hormonal response in bone turnover and calcium homeostasis 
(Kasper et al, 2005). PTHrP is seen to exert important development 
influences on foetal bone development and in adult physiology. A 
homozygous knockout of the PTHrP gene in mice causes a lethal deformity 
in which animals are born with severe skeletal deformities resembling 
chondrodysplasia [8]. Additionally, the lactating breast in humans 
secretes PTHrP, and this hormone is present in very high concentrations in 
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milk (Boron and Boulpael, 2012). PTHrP may promote the mobilization of 
calcium from maternal bone during milk production (Boron and Boulpael, 
2012). 
 
3.5 Potassium 
There appears to be an association between potassium and calcium/bone 
homeostasis through observational studies and randomized controlled trials. 
The most promoted hypothesis for a bone benefit of potassium is through its 
effect on acid-base balance. There appears to be a complex interaction 
between the interstitial fluid that surrounds the crystalline bone, and the 
systemic extracellular fluid. The bone’s interstitial fluid has higher 
concentrations of potassium and sodium, and lower concentrations of 
calcium and phosphorous, compared with plasma (Tylavsky et al, 2008). 
The potassium content of the bones’ interstitial fluid appears to be directly 
related to the quantity of potassium consumed, and is the skeletal 
compartment’s first line of defense in buffering metabolic acid loads 
(Tylavsky et al, 2008; Green et al, 1991). 
 
 Alkaline potassium salts produced from metabolizing fruits and vegetables 
and potassium supplements appear to protect against bone resorption from 
low grade metabolic acidosis from western diets or other insults, by 
neutralizing the acid (Wever et al, 2013). In addition, potassium intake has 
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been associated with reduced urinary calcium excretion, suggesting that 
potassium may have a role beyond its alkalization effect (Dawson-Hughes B 
et al, 2009). The positive effect of potassium on bone could be through 
either the suppression of calcium resorption, bone mineral dissolution, or 
both (Wever et al, 2013). Studies by Sebastian et al in post-menopausal 
women receiving potassium suggested that this improved calcium balance, 
and reduced net renal acid excretion. Further, a trial by Jehle et al 
demonstrated that potassium citrate given at 50mmol/day over 2 years 
improved bone mineral density and bone microarchitecture in 201 elderly 
men and women (Jehle et al, 2013). 
 
3.6 Gonadal steroid hormones  
Gonadal hormones (oestrogen and testosterone) are not directly involved in 
regulation of plasma calcium, but they contribute to the overall long term 
maintenance of normal bone mass after puberty. In the absence of gonadal 
steroids, calcium is steadily lost from bones, leading to osteoporosis (Moffett 
et al, 1993). In males, levels of testosterone are adequately maintained to 
reduce the chance of osteoporosis despite a fall in secretion of testosterone, 
however in females, oestrogen levels fall below the level that maintains bone 
mass, particularly after menstruation, or if reproductive cycles are 
interrupted by an eating disorder or intensive athletic training (Moffett et al, 
1993).  
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Chapter 4: Pathophysiology of parathyroid 
glands in chronic (end stage) renal failure 
The kidney is essential for maintaining the homeostasis of divalent ions and 
the metabolism of vitamin D. They act to maintain the balance for calcium, 
phosphorus and magnesium and they are the principal tissues responsible for 
hydroxylating 25-hydroxyvitamin D to 1, 25-dihydroxyvitamin D and 24, 
25-dihydroxyvitamin D. With the progressive chronic reduction in the 
glomerular filtration rate, renal hyperparathyroidism ensues. About 10-30% 
of patients with chronic renal failure undergo parathyroidectomy to control 
secondary and tertiary hyperparathyroidism. Secondary hyperparathyroidism 
is defined as excess PTH secretion from parathyroid glands from a persistent 
hypocalcaemic stimulus arising from end stage renal failure. Tertiary 
hyperparathyroidism is defined by either (a) Excess PTH secretion resulting 
in hypercalcaemia in end stage renal failure or (b) autologous excess PTH 
secretion, despite corrective measures with renal transplant. This percentage 
has remained constant over the last twenty years despite advances in medical 
therapy (Parfrey et al, 2013). The pathophysiology of this disorder is 
complex and involves a number of feedback loops between the kidneys, 
bone, intestine and the vasculature. The main goal of this system is 
maintenance of calcium and phosphorous balance, often at the expense of 
abnormalities in other components of the system (Berkoben and Quarles, 
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2015). Several interrelated factors are thought to be involved in the 
pathogenesis of refractory hyperparathyroidism, including phosphate 
retention, decreased free ionized calcium concentration, decreased 1,25-
dihydroxyvitamin D (calcitriol) concentration, increased fibroblast growth 
factor 23 (FGF-23) concentration, reduced expression of vitamin D receptors 
(VDRs) and calcium sensing receptors (CaSRs), and hyperplasia of 
parathyroid glands (Jowsey et al, 1974). Renal osteodystrophy appears to be 
an almost universal phenomenon resulting from persistent secondary and 
tertiary hyperparathyroidism, which is a high state of bone turnover, leading 
to osteitis fibrosa, usually characterized by increased osteoclast and 
osteoblast activity and peri-trabecular fibrosis.   
 
4.1 Pathophysiology of chronic renal failure-mineral bone 
disease- secondary hyperparathyroidism 
4.1.1. Phosphate retention  
Many investigators have demonstrated that phosphorous retention in the 
course of renal failure plays an important role in the pathogenesis of renal 
hyperparathyroidism (Jowsey et al, 1974, Rutherford et al, 1977, Slatopolsky 
et al, 1971). While it was initially proposed that phosphate retention would 
give rise to a decrease in the levels of ionized calcium that would stimulate 
PTH release, additional observations have indicated that hypocalcaemia is 
not necessary for hyperparathyroidism to develop and therefore point to the 
fact that other consequences of phosphate retention are likely to be important 
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(Rutherford et al, 1977). Nonetheless, it has been clearly demonstrated that if 
phosphate in the diet is restricted in proportion to the decrease in kidney 
function, hyperparathyroidism can in part, be reversed (Rutherford et al, 
1977, Aly et al, 1995). The mechanism whereby phosphate retention leads 
to hyperparathyroidism is not certain. From the viewpoint of phosphate 
homeostasis, the initial elevation of PTH secretion is appropriate since the 
ensuing increase in phosphate excretion lowers the plasma phosphate 
concentration toward normal. Among patients with severely reduced eGFR, 
PTH inhibits proximal tubule phosphate reabsorption from the normal 80-
95% to as low as 15% of the filtered phosphate (Cunningham et al, 2011, 
Slatopolsky et al, 1971). In addition, it is possible that phosphate retention 
could serve to decrease the production of calcitriol production, and the 
consequences of reduced calcitriol production could contribute to 
hyperparathyroidism. Other investigators have demonstrated that hyper-
phosphataemia stimulated parathyroid gland growth, and that elevations in 
phosphate stimulated the secretion of PTH independent to changes in the 
levels of ionized calcium (Slatopolsky, 1996, Almaden et al, 1999). The 
stimulation of parathyroid growth by a high phosphate load appears to be 
associated with increased expression of transforming growth factor alpha 
(TGF-α), which acts on the epidermal growth factor receptor (EGF-R) to 
activate mitogen-activated protein (MAP) kinase and stimulate cell 
proliferation (Dusso et al, 2001). This effect of phosphorous appears to be 
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post-transcriptional and to be mediated by alterations within the parathyroid 
cell that affect the stability of PTH messenger RNA (Aly et al, 1995). An 
alteration in dietary phosphate intake has also been shown to regulate the 
expression of the calcium sensing receptor in the parathyroid gland and 
thereby influence the response of the parathyroid to changes in serum 
calcium (Aly et al, 1995). Overt hyperphosphataemia does not generally 
appear in patients with renal failure until their renal function decreases to 
below 25% normal. This is probably due to maintenance of 
normal phosphataemia as a consequence of increased levels of PTH in 
promoting phosphate excretion from the kidneys above this renal function 
level. However, with long term reduction of eGFR, since phosphate 
reabsorption by the renal tubules cannot be lowered down below a minimum 
threshold, continued PTH-induced release of phosphate form bone leads to 
exacerbation of hyperphosphataemia (Berkoben  AND Quarles, 2015).   
 
4.1.2. Decreased calcitriol activity  
Plasma calcitriol concentrations generally fall below normal when 
the eGFR is <60ml/min, although low concentrations have also been found 
in some patients with higher eGFR <80ml/min (Levin et al, 2007). 80% of 
chronic renal failure patients are thought to be vitamin D deficient.  Initially, 
the decline in calcitriol concentration is likely to be due to the increase in 
fibroblast growth factor-23 (FGF-23) concentration rather than the loss of 
functioning renal mass. The FGF-23 induced decrease (by suppressing the 
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activity of 1-alpha hydroxylase) in calcitriol begins early, when 
the eGFR drops to <70ml/min, however in advanced renal 
failure, hyperphosphataemia and loss of renal mass may also contribute to 
the decline in calcitriol synthesis (Berkoben and Quarles, 2015). Phosphate 
retention can directly suppress the renal synthesis of calcitriol by inhibiting 
1-alpha-hydroxylase activity (Llach, 
1995). Hyperphosphataemia stimulates the secretion of FGF-23 (primarily 
by bone osteocytes) which act on target tissues by binding onto its receptor. 
Thus, this provides a trigger for increased PTH production from the 
parathyroid glands (Berkoben and Quarles, 2015).  
 
Inability of the diseased kidney to produce calcitriol plays an important role 
in the pathogenesis of altered calcium homeostasis in renal insufficiency 
(Coburn et al, 1976).  In patients with advanced renal failure, the intestinal 
absorption of calcium is impaired and the plasma levels of calcium 
and calcitriol are uniformly depressed. Moreover, the administration of 
modest doses of calcitriol can restore the intestinal absorption of calcium to 
normal uraemic patients (Yuen et al, 2016, Liebross and Coburn, 1982).   
 
A demonstration of vitamin D deficiency resulting in parathyroid hyperplasia 
and increased PTH synthesis comes from studies whereby administration of 
calcitriol inhibits parathyroid gland growth, prevention of the decrease in 
parathyroid vitamin D receptor (VDR) expression and control of PTH. 
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Binding of calcitriol to VDR resulted in trans-repression of the PTH gene 
and increased mRNA levels for VDRs, due to calcitriol induction of CEBPβ, 
a trans-activator of the VDR gene in renal cells and in osteoblasts (Dhawan 
et al, 2005, Dusso and Brown, 2009). It also prolonged the VDR half-
life through ligand dependent protection of the VDR 
from proteosomal degradation (Wiese et al, 1992). In addition, it appears that 
calcitriol interaction with VDR also stimulated induction of calcium sensing 
receptor (CaSR) gene. In rats, parathyroid CaSR mRNA levels were 
decreased by 40% by vitamin D deficiency, and enhanced by calcitriol 
treatment in a time and dose dependent manner (Dusso and Brown, 2009). 
Thus, in chronic renal failure, both parathyroid levels of CaSR and 
VDR receptor levels decrease, which reduces the inhibitory ability of 
calcium and calcitriol to PTH release. Simultaneously, the parathyroid 
glands undergo hyperplasia, and with progressive disease, it forms nodules 
(nodular hyperplasia), the most severe form of secondary 
hyperparathyroidism, insensitive to high calcium and calcitriol suppression 
of either PTH or cellular growth (Dusso and Brown, 2009).   
 
4.1.3. Skeletal resistance to the calcaemic action of parathyroid hormone  
Another factor which contributes to hypocalcaemia and the degree of 
secondary hyperparathyroidism in renal failure is skeletal resistance to 
calcaemic action of PTH. Thus, a higher concentration of PTH may be 
required to maintain serum calcium at normal levels. In patients with 
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advanced renal failure and in those treated with dialysis, the administration 
of exogenous parathyroid extract fails to produce a normal increment rise of 
serum calcium (Massry et al, 1973). In addition, patients with mild renal 
insufficiency exhibit delayed recovery form the hypocalcaemia induced by 
the infusion of ethylenediamie tetracetic acid (EDTA) despite a greater than 
normal increment rise in serum PTH (Kraut et al, 1981). Resistance to 
PTH appears to be multifactorial, but is likely due to downregulation of PTH 
receptors induced by the high circulating PTH concentrations, calcitriol 
deficiency and hyperphosphatemia (Rodriguez et al, 1991). Also, PTH 
fragments with a truncated N-terminus, previously considered to have no 
biological action, may actually be involved in the regulation of skeletal 
metabolism (Aly et al, 1995). The actions of such N-
terminally truncated PTH fragments appear to oppose the calcaemic effects 
of PTH; their accumulation the serum in renal failure could therefore 
contribute to skeletal resistance to PTH (Aly et al, 1995). One such fragment, 
PTH 7-84 has  been shown in vitro to be a potent inhibitor of stimulated 
bone resorption due to PTH, calcitriol, interleukin 11 or prostaglandin E2 
(Divieti et al, 2001).  
 
4.1.4. Decreased fibroblast growth factor 23  
Fibroblast growth factor 23 (FGF-23) is a circulating peptide that plays a role 
in the control of serum phosphate concentrations. It is secreted by bone 
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osteocytes and osteoblasts influenced by serum calcitriol, phosphate, PTH 
and calcium levels and its key function is to maintain normal phosphate 
concentration by reducing phosphate reabsorption and by reducing intestinal 
phosphate absorption through decreased calcitriol production (Qunibi et al, 
2015). In the kidneys, FGF-23 binds to its receptor (FGF-R) and its co-
receptor, klotho, causing inhibition of the expression of the Na/Pi 
cotransporter. Klotho, a transmembrane protein, is required for FGF-23 
receptor activation (Urakawa et al, 2006). In addition, FGF-23 also inhibits 
expression of 1-alpha-hydroxylase enzyme, leading to reduced calcitriol 
production from the kidneys (Qunibi et al, 2015). It also appears that FGF-23 
directly suppresses PTH production, however in chronic renal failure, the 
presence of high PTH concentrations suggests that the parathyroid gland is 
relatively resistant to the elevated concentrations of FGF-23 in uraemia 
(Qunibi et al, 2015).   
 
Patients with chronic renal failure appear to have increased FGF-23 
concentrations due to phosphate retention and decreased clearance. Klotho 
expression declines early and progressively in the course of renal failure, 
whist the concentration of FGF-23 elevates, suggesting there is a direct 
inverse relationship between these two. Moreover, the decrease in klotho 
expression on hyperplastic parathyroid glands may contribute to the 
resistance and impaired parathyroid suppression by FGF-23 (Qunibi et al, 
2015, HU et al, 2011).   
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4.2 Tertiary hyperparathyroidism 
In some patients with longstanding secondary hyperparathyroidism, they 
develop markedly elevated PTH levels associated with hypercalcaemia, 
unexplained by the administration of calcium or calcitriol to counteract it. 
Such patients are known to have tertiary hyperparathyroidism, who are often 
refractory to medical therapies due to the autonomous secretion of PTH that 
is no longer responsive to the plasma calcium concentration (Qunibi et al, 
2015). Tertiary hyperparathyroidism is often seen in the context of renal 
transplantation (in the view to correct secondary hyperparathyroidism), 
whereby 15-50 per cent of transplanted patients after their first year still have 
hyperparathyroidism, which is unlikely to improve spontaneously (Dulfer et 
al, 2017).  Its occurrence is thought to be related to the severity of pre-
transplant hyperparathyroidism and duration of dialysis prior to 
transplantation (Park et al, 2011). In patients with tertiary 
hyperparathyroidism, reduced expression of CaSR and VDRs leads to a lack 
of suppression of PTH by calcium and vitamin D, which results in prolonged 
stimulation of parathyroid gland hyperplasia (Qunibi et al, 20150. Nodular 
parathyroid hyperplasia may result, which is resistant to regression despite 
resolution of the triggering mechanisms (such as medical therapy or after 
renal transplantation). 
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4.3 Clinical manifestations of renal hyperparathyroidism  
Clinical manifestations of renal hyperparathyroidism are usually non-specific 
and often preceded by biochemical or imaging abnormalities.   
 
4.3.1. Musculoskeletal symptoms  
In patients with advanced renal insufficiency who have severe bone disease, 
bone pain is a common manifestation. This is often nonspecific in nature, 
and occurs in the lower back, hips, legs, and is aggravated by weight bearing 
(Gonzalez and Martin, 2000). Acute, localized bone pain can also become 
manifest and may be suggestive of acute arthritis. Pain around joints may be 
caused by acute peri arthritis, which is associated with periarticular 
deposition of calcium phosphate crystals, especially in patients who suffer 
from marked hyperphosphatemia (Gonzalez and Martin, 2000). The 
symptoms may be confused with gout or pseudo-gout.   
 
Proximal muscle weakness is usually of gradual onset and may be severe and 
debilitating in some patients with advanced renal failure. Muscular weakness 
may be so profound that affected individuals may have difficulty getting up 
from a sitting position (Heptinstall, 1983). The plasma levels of muscle 
enzymes are normal and there are no characteristic abnormalities on 
electromyography (Aly et al, 1995). Proximal myopathy and muscle 
weakness may be related to secondary hyperparathyroidism, phosphate 
depletion and vitamin D deficiency. Muscle weakness may also arise as a 
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result of peripheral neuropathy, electrolyte disturbances, iron overload and 
carnitine deficiency. Spontaneous tendon rupture has been observed in 
patients with long-standing renal disease in dialysis (Aly et al, 1995). The 
quadriceps, triceps and Achilles tendons have been most commonly 
implicated. Involvement of the extensor tendons of the fingers has also been 
described. The proximal muscle weakness is to a large extent, reversed by 
parathyroidectomy, which abolishes the PTH elevation. How the PTH relates 
to the causation of this myopathic weakness remains incompletely 
understood.  
 
Spontaneous fractures most commonly affect the axial skeleton where they 
involve the vertebral bodies, ribs and hips. Such fractures are most 
commonly associated with ostomalacia (low bone turnover and poor 
mineralization), adynamic bone disease (low turnover pathology with normal 
mineralization) and/or ostitis fibrosa cystica (high bone turnover), 
collectively known as renal osteodystrophy (Yuen et al, 2016).  Fractures 
often occur with minimal trauma. Thus, crush vertebral fractures may occur 
spontaneously, rib fractures can occur during a sneeze/cough, and hip 
fractures may occur such as when a patient steps off a curb. Less frequently, 
fractures involve the long bones (Liebross and Coburn, 1982). Spontaneous 
rib fractures are frequently multiple, and little displacement may be seen in 
chest x ray, hence, they are more easily visualized with a bone scan, 
indistinguishable from stress fractures or pseudo fractures (Liebross and 
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Coburn, 1982). With longstanding bone resorption, patients may develop 
localized regions of bone loss that are often replaced by fibrous tissue, 
resulting in a brown tumour (Yuen et al, 2016). These brown tumours appear 
as well defined lytic lesions on x ray and may be mistaken for metastasis 
(Figure 16)  
 
Figure 16. X ray of a 55 year old patient with renal osteodystrophy and 
brown tumours of the fourth metacarpal and third proximal phalanx of the 
left hand (arrows) (Liebross and Coburn, 1982) 
 
4.3.2. Pruritus  
This is especially common and troublesome in patients who have chronic 
renal failure. Substantial or total improvement may follow after 
parathyroidectomy. The mechanism responsible for pruritus is also not well 
understood, and may be related to a change in the calcium content of the 
skin. However, the treatment of severe pruritus is often symptomatic, but is 
an indication for consideration for parathyroidectomy.  
 
4.3.3. Metastatic calcification  
There are two forms of extra-skeletal or metastatic calcification (1) 
amorphous calcium phosphate, found in soft tissues such as heart, lung and 
kidney and (2) hydroxyapatite, similar to that of normally calcifying tissue 
present in vascular, valvular, joint and ocular tissues. Metastatic and extra-
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skeletal calcifications can occur in damaged tissue (dystrophic calcification) 
or in apparently normal tissue (Aly et al, 1995). This calcification occurs in a 
variety of tissues both visceral and non-visceral, including skin, cartilage, 
heart, lungs, kidneys, and shoulders, limbo-conjunctival, vascular and 
valvular tissues (Aly et al, 1995). Calcification of the cardiovascular tissue 
can affect the myocardium, atrial-ventricular conduction, and valvular 
function (Liebross and Coburn, 1982). This has significantly received 
attention as they have been linked to increased risk of cardiovascular events 
and death in chronic renal failure (Aly et al, 1995, Wang et al, 2003).  
 
4.3.4. Calciphylaxis  
Calciphylaxis is an unusual yet devastating syndrome characterized by skin, 
fat, digit and limb necrosis that is attributed to medial calcification of small 
and medium sized arteries. This condition has been described in patients with 
end stage renal failure, particularly on long term dialysis and it usually 
occurs in the setting of uncontrolled hyperparathyroidism. The skin lesions 
initially manifest as painful nodules with peau d’orange changes which may 
become mottled with violaceous discolouration similar to livedo reticularis, 
and can subsequently become infected. The lesions can be found in the distal 
extremities, involving the toes, fingers or ankles, or they may be localized in 
proximal areas such as thigh, buttocks, abdominal wall or breasts (Aly et al, 
1995). Histologic examination of the involved skin demonstrates medial 
calcification of small and medium sized vessels. The pathogenesis of this 
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lesion is obscure, however since these lesions are similar to those seen with 
warfarin induced skin necrosis, a role for altered coagulation, particularly in 
the protein C and S pathway in the final manifestations of this issue has been 
considered. Patients on dialysis with calciphylaxis have been noted to have 
decreased protein C and protein S activity (Kant et al, 1992). On the 
whole, calciphylaxis presents as a serious complication, since disseminated 
infection from tissue necrosis is the most common cause of death. In 
general, calciphylaxis carries a very poor prognosis, even after 
parathyroidectomy (Gonzalez and Martin, 2000).   
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Chapter 5: Investigations and preoperative 
localisation of parathyroid glands 
5.1 Investigations  
These are planned in the first instance to establish whether there is 
hypercalcaemia, to assess the extent of hyperparathyroidism and gauge the 
severity of renal osteodystrophy. For dialysis patients, the suggested target 
goals are (Quarles and Berkoben, 2015):  
 Serum levels of corrected calcium levels should be maintained 
between 2.10-2.37mmol/L;  
 Serum levels of phosphate should be maintained between 1.13-
1.78mmol/L;  
 Second generation PTH assay should be maintained between 2.5 to 5 
times the upper limit of normal.  
 
5.1.1. Plasma calcium  
Although ionized calcium is the physiologically active component regulating 
PTH secretion, its measurement presents technical difficulties and is not 
routinely measured. Generally, the sum of ionized, protein bound and 
complexed forms is measured (referred to plasma calcium), however current 
assays can provide plasma calcium levels minus the bound albumin 
component (referred to plasma corrected calcium) (Toft et al, 1981). 
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Changes in H+ concentration may affect plasma calcium levels by altering 
the distribution between ionized and protein-bound forms, independent of a 
disturbance of calcium homeostasis (Toft et al, 1981). The average serum 
calcium level of patients with advanced renal failure is lower than that 
measured in a control population, however dialysis dependent chronic renal 
failure patients often have hypercalcaemia due to secondary or tertiary 
hyperparathyroidism. It may be associated with excess intake of oral calcium 
and treatment with various vitamin D sterols, and it is not uncommon in 
patients with the syndrome of 'dialysis osteomalacia’ (Heath and Marx, 
1982). Changes in plasma calcium in response to dairy intake are small, but 
it is preferable to collect specimens under fasting conditions.  
 
 5.1.2. Serum phosphate  
Serum phosphate generally is normal in early renal failure, however as the 
eGFR falls to less than 25% of normal, patients 
become hyperphosphataemic. At this degree of renal failure, changes in 
dietary phosphate intake can greatly contribute to the degree of serum 
phosphate levels (Heath and Marx, 1982). In addition, it is usually necessary 
to treat patients with oral phosphate binders. Treatment with calcitriol can 
also stimulate the absorption of both phosphate and calcium from the 
intestine, and thus may aggravate hyperphosphataemia (Heath and Marx, 
1982). It may be intuitive to think that hyperphosphataemia stimulates the 
production of PTH from parathyroid glands to provide a phosphaturic action, 
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however at eGFR levels <10ml/min, this physiological counteraction 
appears de-functional secondary to end stage renal failure.  
 
5.1.3. Parathyroid Hormone  
PTH levels are a direct measure of parathyroid gland function, and an 
indirect measure of bone remodelling. Full length PTH has a half-life of 2-4 
minutes, which it is cleaved into an inactive C-terminal fragment, an active 
N-terminal fragment, and an inactive mid-region fragment in the peripheral 
tissues (Gilbert et al, 2014). A two-site immunoassay is currently used to 
measure circulating PTH concentrations, utilizing two antibodies. One 
antibody detects an epitope near the N-terminus, and the other detects the C-
terminal end. The assay actually detects the full length bioactive PTH (1-84) 
and PTH fragments such as PTH (7-84), albeit the non-biologic 
fragment (Gilbert et al, 2014). Newer, second generation immuno-
active PTH assays are also available that recognize amino acids 1-4 of the N-
terminus, and specifically detect full length PTH (1-84) (Gilbert et al, 
2014).  PTH levels greater than 31.50pmol/L generally correlate with bony 
changes of secondary hyperparathyroidism and/or osteitis fibrosis. PTH is 
also a crude, indirect measure of bone turnover, however alkaline 
phosphatase levels can be used in conjunction to determine the degree of 
osteoblastic activity (Gilbert et al, 2014).   
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5.1.4. Alkaline phosphatase  
The total serum alkaline phosphatase reflects enzyme activities arising from 
hepatic, intestinal and skeletal sources. Despite the non-specific nature of 
alkaline phosphatase, a slow progressive increase in serum level in end stage 
renal failure may be the only clue to the development of overt bone disease 
(Heath and Marx, 1982). The skeletal alkaline phosphatase arises largely 
from osteoblasts, and a correlation between skeletal alkaline phosphatase and 
bone biopsy findings of osteitis fibrosa has been observed (Heath and Marx, 
1982, Pierides et al, 1979).   
 
5.1.5. Serum magnesium  
The levels of serum magnesium tends to increase as the eGFR falls below 
20-25% of normal. Acute hypermagnesemia may occur in end stage renal 
failure patients following an increase in dietary magnesium intake and those 
ingesting magnesium containing antacids (Heath and Marx, 1982).   
 
5.1.6. Radiology  
Radiographic studies are generally not required in the diagnosis of bone 
disorders secondary to renal hyperparathyroidism, although certain 
radiographic changes can be seen. Sub periosteal erosions of the phalanges 
and of the terminal digits tufts can often be seen on hand x ray, and these 
changes may also be present in the outer third of clavicle, both the neck and 
distal end of the femur and the upper end of the tibia (Toft et al, 
81 
 
1981). Expansile lytic lesions (brown tumours), as well as cysts which may 
be solitary or multiple in long bones may be seen in severe osteitis 
fibrosis cystica (Figure 14).   
 
There is no accurate correlation between bone mineral density (BMD) as 
measured by dual energy X ray absorptiometry (DEXA) and the type of 
chronic renal failure associated bone disease present (Gilbert et al, 2014). 
Although patients with chronic renal failure typically have lower BMDs than 
the general population, the interpretations of DEXA scans are further 
complicated in secondary hyperparathyroidism because of focal areas 
of osteosclerosis, the presence of extra-skeletal calcifications and the 
variable presence of osteomalacia (Gilbert et al, 2014). However, analysis of 
BMD at distal sites, such as the distal radius, or the hip may be useful in 
assessing fracture risk in chronic renal failure. BMD may also be considered 
in patients who have undergone renal transplantation, or who have known 
risk factors or previous fractures and are candidates for osteoporosis therapy 
(Gilbert et al, 2014).   
 
5.2 Preoperative localisation of parathyroid glands  
The diagnosis of hyperparathyroidism is established by the patient’s 
symptoms and biochemical data, and is not influenced by a positive or 
negative result of any parathyroid imaging modality. A single focus positive 
imaging result does not reliably exclude the presence of multi-glandular 
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parathyroid disease (Yip et al, 2015). Likewise, medical or surgical 
management decisions are made according to the severity of the disease 
with the goal of parathyroidectomy the restoration of normo-calcaemia and it 
should not be postponed if a parathyroid abnormality is not portrayed in 
imaging tests (Moralidis, 2013).   
 
However, unlike the well-studied role of localization studies in patients with 
primary hyperparathyroidism, little is known about the usefulness in patients 
with secondary and tertiary hyperparathyroidism. Most of the published 
literature is in the form of small case series. Considering that the majority of 
patients with renal hyperparathyroidism will require a bilateral neck 
exploration, and the fact that the parathyroid glands are larger than seen in 
primary hyperparathyroidism, the utility of localizing studies 
is unproven (Alkhalili et al, 2015). Additionally, the sensitivity of imaging 
studies has been reported to be lower than in primary hyperparathyroidism, 
where the preoperative use of combined neck ultrasound, parathyroid 
scintigraphy and/or four dimensional computed tomography (4D-CT) has 
recently been proposed for minimally invasive explorations (Fuster et al, 
2006, Lumachi et al, 2001). On the other hand, the relatively small size of 
some hyperplastic or adenomatous glands and the common occurrence of 
unexpected ectopic and/or supernumerary glands have led to a relatively high 
rate of reoperation due to missed glands located in the neck (Fuster et al, 
2006). This also raises the question of the need to perform preoperative 
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imaging in order to increase the success rate of surgery in renal 
hyperparathyroidism (Fuster et al, 2006).  
 
In light of poor sensitivity, most surgeons do not opt for any preoperative 
imaging, and believe that the best localizing tool is to 'localize an 
experienced parathyroid surgeon'. However, if imaging modalities are 
employed, the most commonly used are ultrasound, parathyroid scintigraphy, 
CT and/or MRI.  
 
5.2.1. Ultrasound  
Neck ultrasonography is often utilized for localisation (Figure 17). 
However, the accuracy of ultrasound is invariably operator dependent. In one 
prospective study, the sensitivity and specificity of detecting 
hyperplastic parathyroids in uraemic hyperparathyroidism was reported as 
62% and 95% respectively, and had a 0% detection rate of ectopic 
glands (Vulpio et al, 2010). In another study, the sensitivity and specificity 
of sonography for detection of secondary hyperparathyroidism were 62.5% 
and 85.7%. It also concluded that high resolution US provided significant 
correlation between enlarged parathyroid glands and parathyroid 
hormone level (Anari et al, 2011).  
 
Ultrasound based scores have also been reported to be useful as predictors 
for nodular hyperplasia in patients with 
secondary hyperparathyroidism (Gwiasda et al, 2017). Studies by Gwisda et 
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al 2017 was able to use characteristics of blood flow patterns and echo-
structure of hyperplastic parathyroid glands to identify nodular hyperplasia, 
indicating the need for surgical or ablative treatment when failing 
conservative therapy.   
 
As with radio-nucleotide based techniques, the sensitivity of ultrasound for 
parathyroid localization is reduced in patients with concurrent thyroid 
nodules. However, ultrasound is helpful for the characterization and 
evaluation of any thyroid pathology, facilitating operative planning (Yip et 
al, 2015). This is a common problem, since concurrent thyroid pathology is 
present in 20-30% of patients with hyperparathyroidism (Bentrem et al, 
2002). In addition, ultrasound directed fine needle aspiration with analysis of 
PTH levels can be useful for confirming suspected parathyroid lesions such 
as intra-thyroidal glands (Yip et al, 2015).   
 
Figure 17. (a) Initial (left) and delayed (right) phase of the 99mTc-MIBI 
study demonstrating fixed uptake of right inferior, left superior and inferior 
enlarged parathyroid glands. (b) Ultrasound of neck corresponding to left 
inferior (left) and left superior (right) parathyroid glands, measuring 
3.9x3.3mm and 3.4x3.3mm respectively (Fuster et al, 2006) 
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5.2.2. Parathyroid scintigraphy  
Generally, 99mTc-sestamibi scintigraphy (MIBI) alone provides poor yield 
in localizing hyperplastic parathyroid glands. Vulpio et al 2010 reported 
sensitivities lower than ultrasound scans (55% vs 62%).  A similar result was 
reported in Lee et al 2016 where they reported sensitivities as low as 56.1%. 
Often, ultrasound and MIBI scans are combined to improve sensitivity, with 
reported sensitivities of up to 73% (Vulpio et al, 2010) (Figure 17).   
 
Most centres have adopted sestamibi-single photon emission computed 
tomography (SPECT), a three dimensional scan that provides higher 
resolution imaging and improves performance of sestamibi (MIBI) scanning 
(Yip et al, 2015). SPECT is often combined with CT as SPECT/CT (Figure 
19). A recent study of sixty patients with secondary hyperparathyroidism 
demonstrated that SPECT/CT sensitivity, specificity and accuracy was 85%, 
58% and 89%, significantly higher than compared with ultrasound alone 
(Kawata et al, 2009). When combined with SPECT/CT and ultrasound 
together, this improved sensitivity, specificity and accuracy to 93%, 61% and 
97% (Kawata et al, 2009).   
 
As recurrent disease (from ectopically placed glands) is more frequent in 
patients with renal hyperparathyroidism, preoperative MIBI imaging has 
been advocated to detect ectopic or supernumerary glands. However, the 
diagnostic yield of this modality is no more than moderate in eutopic gland 
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hyperplasia; whereas many surgeons assert that the identified aberrant glands 
are usually located in sites that are routinely explored during surgery 
(Moralidis, 2013). A recent study reported that both ultrasound and 
scintigraphy failed to identify 61.5% ectopic glands, and scintigraphy was 
able to identify 69.7% of all ectopic glands located in the mediastinal and 
thymic regions (de Andrade et al, 2014). However, in postoperative 
recurrence, scintigraphy is superior to other imaging techniques in the 
detection of abnormal foci, and particularly advantageous is the use of 
SPECT/CT (Moralidis, 2013). PET/CT or MRI may be used if previous 
investigations have been negative, or more invasive modalities such 
as selective venous sampling are justified when imaging tests are fruitless 
(Moralidis, 2013).  
5.2.3. Four Dimensional Computed Tomography (4D-CT) 
Increasingly, 4D-CT is being used as an adjunct for preoperative localization 
of parathyroid glands. This technique combines standard multi-planar CT 
scanning with a fourth dimension consisting of changes in contrast 
attenuation over time. This involves perfusion information derived from non-
contrast, arterial, post-contrast and delayed phases (Ellika et al, 2013) 
(Figure 18). Parathyroid glands and adenomas receive contrast enhanced 
blood flow a few seconds earlier than the thyroid tissue, combined with a 
slightly higher flow, which allow parathyroid adenomas to “lighten up” 
earlier than thyroid tissue, and also washes the contrast out earlier 
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(Lundstroem et al, 2016). As a result, 4D-CT provides both functional and 
anatomic information about the abnormal gland, whist permitting unbiased 
detection of ectopic or multi-glandular disease that may be missed by other 
imaging techniques (Bann et al, 2015). The first results of this modality was 
published by Rodgers et al in 2006, who demonstrated significantly greater 
sensitivity (88%) than sestamibi imaging (65%) and ultrasonography (57%) 
for localization of hyper-functioning parathyroid glands (Rogers et al, 2006). 
In an Australian study of 99 patients who had adenomas, the overall 
sensitivity of 4D-CT was 92% compared to 70% for sestamibi (Brown et al, 
2014). The sensitivity of 4D-CT was 76% in those patients who had a 
negative sestamibi, and 91% for the re-operative cases (46% for sestamibi) 
(Brown et al, 2014). Up to 62% of those patients with negative sestamibi 
scans potentially avoided a bilateral neck exploration following a positive 
4D-CT (Brown et al, 2014).  In a survey of 361 radiologists conducted by 
Hoang et al, 2016, 55% of the radiologists utilized 4D-CT in their practice 
for localization of parathyroid adenomas. 10% used 4D-CT as the first line 
imaging study, 76% reported that 4D-CT played a secondary role, and 13% 
performed routinely in combination with ultrasound and scintigraphy (Hoang 
et al, 2016). 
 
However, the major concern with 4D-CT is the radiation dosage delivered to 
the patient. In a study by Hoang et al, 2014, it was reported that the effective 
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dose (ED) of 4D-CT was more than double that of scintigraphy (28mSv vs 
12mSv). Organs receiving the highest radiation dose were the thyroid 
(150.6mGy) and salivary glands (137.8mGy). For scintigraphy, the highest 
organ doses were to the colon (41.5mGy), gallbladder (39.8mGy) and 
kidneys (32.3mGy). The risk of carcinogenesis is of particular relevance in 
the younger patient group. 
 
To this date, studies and use of 4D-CT have been largely confined to 
parathyroid adenomas from primary hyperparathyroidism. There currently no 
reports of its utility in preoperative localization of parathyroid hyperplasia in 
renal hyperparathyroidism. 
 
Figure 18. 4D-CT images of non-contrast (A), arterial phase (B) and delayed 
phase (C). (D) demonstrates a time-attenuation curve demonstrating rapid 
contrast enhancement and washout from the adenomatous gland. Yellow 
arrow indicates a left parathyroid gland (Bann et al, 2015). 
 
5.2.4. Magnetic resonance imaging (MRI)  
MRI is seldom used in preoperative localization of the parathyroids, as 
cervical lymph nodes have similar imaging characteristics, which limit the 
accuracy of it (Yip et al, 2015). For re-operative surgery, MRI may provide a 
useful non-invasive imaging modality, with reported sensitivities for 
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abnormal parathyroid tissue from 40-85% (Wakamatsu et al, 2003, Yip et al, 
2015).   
 
5.2.5. Positron emission tomography (PET)  
This modality uses 11C-methionine as a radiotracer to identify pathologic 
parathyroid glands (Figure 17). In a study by Tang et al 2008, the use of 
11C-methionine PET in preoperative localization of pathological parathyroid 
tissue had been shown to be as reliable as MIBI-SPECT, with its clinical 
benefit in providing metabolic and morphological information provided for 
surgical planning, reporting sensitivity of 68% in detecting parathyroid 
hyperplasia (Tang et al, 2008).  The same authors identified that combining 
11C-methionine PET/CT increased the confidence of the surgeon in 
identifying ectopic and supernumerary parathyroid glands, as well as when it 
was in close contact with surrounding structures such as the trachea, the 
oesophagus or cervical bone structures (Tang et al, 2008).  
 
Figure 19. From left to right: 11C-methionine PET trans-axial slice, 
corresponding CT, fused 11C-methionine PET/CT and MIBI-SPECT images 
of a patient with secondary hyperparathyroidism with three pathological 
parathyroid glands (Tang et al, 2008) 
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5.2.6. Selective venous sampling  
This is the most common invasive modality used for parathyroid 
localization. A 1.5-2 fold increase in PTH levels obtained from 
representative cervical or mediastinal vein drainage location compared to 
a peripheral location is considered an abnormal elevation (Yip et al, 2015). It 
is used when all other imaging modalities are negative. In one report of 21 
patients, selective venous sampling provided localisation sensitivities of at 
least 90%, with no false positive results Seehofer et al, 2004). 
 
In summary, investigations prior to parathyroidectomy for renal 
hyperparathyroidism are performed to confirm the presence of the disease, 
degree of elevation of the PTH levels, whether the serum calcium is normal 
or mildly elevated, serum electrolyte post dialysis (usually 1-2 days prior to 
surgery), and assessment of patients’ fitness for surgery for anaesthesia. 
Localization of parathyroid glands through imaging is not always performed, 
unless there is evidence of recurrent hyperparathyroidism following an initial 
incomplete removal of all parathyroid tissue(s). This certainly is the standard 
practice in our institution. 
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Chapter 6: 
Management of renal hyperparathyroidism 
Renal hyperparathyroidism and the associated changes in mineral and bone 
metabolism are among the most challenging complications in patients with 
chronic renal failure, particularly in the most advanced stages of end stage 
renal failure. High phosphate levels, low/normal/high calcium concentrations 
and deficiency in vitamin D play the fundamental role in the pathogenesis of 
the disease (Konturek et al, 2016). In addition, recent studies have identified 
fibroblast growth factor 23 (FGF-23), a bone derived phosphaturic hormone 
as another important factor in the pathogenesis (Shimada et al, 2004).  
 
6.1. Medical Management 
The initial and predominant management in end stage renal failure in 
dialysis dependant patients is medical therapy. This principally involves the 
use of the combination of phosphate binders, vitamin D or active vitamin 
D analogues, and more recently, use of calcimimetics by the nephrologists. 
No single pharmacologic intervention is usually completely sufficient to 
restore disordered calcium and phosphate homeostasis. However, despite 
continuous and intensive medical management to control 
secondary hyperparathyroidism, approximately 15% of patients ultimately 
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require parathyroidectomy after 10 years and 38% of patients after 20 years 
of ongoing dialysis (Foley et al, 2005).  
 
6.2. Surgical Management 
Parathyroidectomy is an effective therapy for patients 
with persistent hyperparathyroidism after renal transplantation. Recent 
research by Komaba et al in 4428 maintenance haemodialysis patients who 
had undergone parathyroidectomy showed that successful surgery may 
reduce the risk for all cause and cardiovascular mortality in haemodialysis 
patients with severe, uncontrolled secondary hyperparathyroidism (Komaba 
et al, 2015). However, a significant proportion of patients after parathyroid 
surgery develop recurrent renal hyperparathyroidism ranging between 10-
30% (Xu et al, 2016). The three common surgical techniques 
employed in parathyroid surgery include subtotal parathyroidectomy, total 
parathyroidectomy with auto transplantation, and total parathyroidectomy 
without auto transplantation.  The most optimal surgical technique is still 
debatable; however the choice is often surgeon/institution dependant, as well 
as if the patient has an existing or planned renal transplant. For patients who 
refuse or cannot tolerate surgical options, percutaneous ethanol injection 
therapy, and percutaneous vitamin D injection therapy have occasionally 
been performed in Japan, however these interventions have not been 
performed as often due to the introduction of cinacalcet.  
93 
 
6.2.1. Indications for parathyroidectomy  
Although medical therapies, including calcimimetics (e.g. cinacalcet) have 
allowed some patients with end stage renal failure to be treated non-
operatively, symptomatic patients with markedly elevated parathyroid 
hormone levels should be referred for parathyroid surgery if they become 
refractory to medical therapy (Milas, 2016).   
 
6.2.2. Symptomatic patients  
Parathyroidectomy is indicated in those patients who have severe 
hyperparathyroidism (PTH>85-140pmol/L) that is refractory to medical 
therapies and is accompanied by:  
 
 Severe hypercalcaemia;  
 Progressive and debilitating hyper-parathyroid bone disease (renal 
osteodystrophy);  
 Refractory pruritus;  
 Progressive extra-skeletal calcification or calciphylaxis;  
 Otherwise unexplained myopathy (in particular, proximal muscle 
weakness). 
 
Parathyroidectomy has been shown to reduce cardiovascular calcification 
and to have a positive impact on blood pressure, anaemia and serum 
lipids (Ivarsson et al, 2015). Improvements in bone density and bone pain 
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also has been reported and been shown to improve long term survival of 
dialysis patients (Ivarsson et al, 2015).  
 
6.2.3. Asymptomatic patients  
It remains unresolved whether parathyroidectomy offers any benefit in 
asymptomatic individuals, although truly asymptomatic patients are rare in 
renal hyperparathyroidism. The PTH level at which surgery is indicated in 
this group is unknown, as the 2009 Kidney Disease: Improving Global 
Outcomes (KDIGO) guidelines did not specify a PTH cut-off (Kdigo, 2015). 
In addition, there have been no randomized controlled trials to date that have 
compared the long term effects of medical versus surgical therapy of 
advanced secondary hyperparathyroidism (Berkoben and Quarles, 2016). 
However, a reason to consider parathyroidectomy in relatively asymptomatic 
individuals with elevated PTH include the realistic prospect of reducing 
cardiovascular disease, better blood pressure control, and reduced need for 
medications for hyperparathyroidism and hyperphosphatemia (Berkoben and 
Quarles, 2016). Parathyroidectomy may also improve bone density and 
reduce the risk of fracture. Multiple case series have reported increased bone 
mineral density after parathyroidectomy (Abdelhadi, 1998, Chou et al, 
2001). One retrospective case controlled study found that parathyroidectomy 
was associated with reduction in hip fractures (0.68, 95% CI 0.54-0.86) and 
all fractures (0.69, 95% CI 0.57-0.84) (Rudser et al, 2007).   
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6.2.4. Patients awaiting transplantation  
Consultation with the transplant unit regarding timing of parathyroidectomy 
is advised. There exists variability among transplant units in regards to 
recommended approach for potential transplant recipients who have 
refractory hyperparathyroidism. Most experts suggest parathyroidectomy for 
secondary hyperparathyroidism with moderate to severe symptoms, 
particularly if a recipient is not imminent. However, transplant nephrologists 
have differing recommendations for patients with mild or no symptoms 
(Berkoben and Quarles, 2016).    
 
The rationale for not performing parathyroidectomy prior to renal transplant 
is that hyperparathyroidism is expected to resolve after transplantation; 
however some patients who have severe hyperparathyroidism prior to 
transplantation have persistent tertiary hyperparathyroidism associated with 
hypercalcaemia after transplantation, up to 50% after 12 months post-
transplant (Berkoben and Quarles, 2016). Persistent hyperparathyroidism and 
hypercalcaemia have been associated with reduced graft function (Messa et 
al, 2011). On the other hand, parathyroidectomy may be safer if performed 
prior to transplantation, as parathyroidectomy performed after transplantation 
has been associated with abrupt deterioration of renal allograft function 
(Rostaing et al, 1997). This phenomenon has also been observed in patients 
with end stage renal disease with residual renal function (Tzanakis et al, 
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2000). To this date, it is still unknown whether long term graft function is 
negatively affected by parathyroidectomy (Berkoben and Quarles, 2016).   
 
6.2.5. Persistent hyperparathyroidism after renal transplantation  
Persistent hyperparathyroidism is reported to occur in approximately 15-50% 
of patients following transplantation, despite removal of the initial stimuli for 
hyperparathyroidism (Borchhardt et al, 2007). There exists large variability 
between institutions regarding treatment of tertiary hyperparathyroidism. 
Parathyroidectomy is the preferred treatment of patients with severe 
hypercalcaemia and/or hypophosphatemia caused by elevations of PTH 
(Yarlagadda et al, 2017). In a multicentre, open-label randomized study, 
subtotal parathyroidectomy was more likely to result in normo-calcaemia at 
12 months compared with medical management with cinacalcet (100% vs 
60% respectively) (Cruzado et al, 2016). Even in the absence of symptoms, 
many nephrologists refer for parathyroidectomy for patients with 
marked hypercalcaemia that is present for more than six months from time of 
transplantation. Some clinicians manage mild hypercalcaemia and 
hyperparathyroidism (PTH that is two to three times upper limit of normal) 
with cinacalcet initially to prevent complications of hypercalcaemia, 
however some nephrologists do not use cinacalcet in any transplant 
recipients and prefer to refer for parathyroidectomy (Yarlagadda et al, 2017). 
However, this approach may lead to surgical treatment of 
hyperparathyroidism that may resolve with long term follow-up (Yarlagadda 
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et al, 2017). If cinacalcet has been tried, and if this group of patients have 
persistent and significant hyperparathyroidism by 6 to 12 months, they 
should be referred for parathyroidectomy.  
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Chapter 7: Surgical techniques for 
parathyroidectomy  
Since the 1960s, there has been ongoing discussion on the most optimal 
surgical procedure for renal hyperparathyroidism. From the viewpoint of the 
patient, the most important goal of all modalities of treating 
hyperparathyroidism, including surgical treatment is the improvement of 
quality of life, and reducing mortality (Konturek et al, 2016). Thus, the 
overall goal is resolution of symptoms of hyperparathyroidism, at the same 
time, ensuring normal calcium and phosphorous metabolism in patients with 
end stage renal disease. The objectives of surgical treatment should thus 
strive for an appropriate balance between the extent of parathyroidectomy, 
prevention of recurrent disease and avoidance of postoperative permanent 
hypoparathyroidism (Konturek et al, 2016). There are three surgical 
procedures for parathyroidectomy: (1) subtotal parathyroidectomy (ST-
PTX), (2) total parathyroidectomy with auto transplantation (TPTX+AT) and 
(3) total parathyroidectomy without auto transplantation (TPTX). No definite 
evidence exists to date in favour of one over the other, as all of the above 
objectives cannot be guaranteed with any one of the techniques (Schneider et 
al, 2014). Often, the choice of procedure is determined solely by 
surgeon/institutional preference.  
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If an inferior parathyroid gland cannot be located, it is most likely located in 
one of the intra-thymic locations. Thymectomy is an important component of 
parathyroid surgery for end stage renal failure patients who have missing 
inferior parathyroid glands because retained intrathymic glands can be the 
source of persistent or recurrent disease (Milas, 2016). Concurrent 
thymectomy is also considered due to the presence of supernumerary glands 
and “rests” in the thymus. In one study, adding a cervical thymectomy 
increased the overall cure rate of hyperparathyroidism from 89 to 94 per cent 
(Boltz et al, 2015).  
 
In regards to intraoperative PTH monitoring, an established protocol does 
not exist for renal hyperparathyroidism, due to delayed renal clearance of 
PTH (unlike the Miami Protocol for primary hyperparathyroidism). 
However, intraoperative monitoring is still used in some institutions to 
provide assurance that all hyper-functioning parathyroid tissue has 
been removed. In one study, a PTH decline of 80% predicted cure (Ohe et al, 
2013), and a post resection PTH level that is high or fails to reduce suggests 
the presence of additional abnormal glands which warrants further resection.  
 
7.1. Subtotal parathyroidectomy  
 ST-PTX is the resection of approximately 3.5 parathyroid glands, leaving 
behind 40-80mg (roughly the size of two normal parathyroid glands) of the 
most normal appearing parathyroid gland, well vascularized in situ after 
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marking it with a non-absorbable suture, or a metallic clip. Sometimes, a 
75% resection of the remnant gland (near total parathyroidectomy) has been 
used, and a more aggressive resection could be attempted when parathyroid 
cryopreservation is available (Milas, 2016). Often, it should be combined 
with bilateral cervical thymectomy, to remove potential supernumerary 
parathyroid glands, which is more common in end stage renal patients in 
an environment of constant PTH stimulus. It appears preferable to save an 
inferior gland as they are usually located more anteriorly in the neck making 
the remnant more accessible to reoperation if necessary (Lorenz et al, 2015). 
The advantages of this technique include preservation of hormonal function 
by the parathyroid with normal blood supply in situ and low rate of 
postoperative permanent hypocalcaemia. Hence, some surgeons prefer ST-
PTX over others in patients who have secondary hyperparathyroidism, who 
are expected to receive a renal transplant in the short term. In the case of 
patients who have a functioning renal transplant with 
tertiary hyperparathyroidism, it provides favourable conditions for such 
procedure, negating any possibility of damage to the transplanted kidney 
from sudden removal of PTH, as well as reducing the risks of iatrogenic 
hypoparathyroidism and hypocalcaemia (Konturek et al, 2016, Lorenz et al, 
2015). The major disadvantages of ST-PTX is a risk of requiring reoperation 
in a technically difficult, scarred up neck when recurrent 
hyperparathyroidism occurs, as well as the necessity of general anaesthesia 
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and the increased risk of recurrent laryngeal nerve palsy/permanent damage 
from loss of tissue planes (Rothmund et al, 1991). A recent meta-analysis 
demonstrated that a need for reoperation in ST-PTX was 8.1%, which was 
not significantly different to TPTX + AT (6.6%) (Chen et al, 2016). Another 
potential risk is of parathyroid necrosis of the remnant, leading to 
hypoparathyroidism. 
 
7.2. Total parathyroidectomy with auto-transplantation  
Some surgeons perform TPTX + AT to reduce the chance of long term 
hypoparathyroidism and the need for long term calcium and vitamin D 
supplementation, as well as to avoid a difficult reoperation in the neck 
induced by hyper-function of autografted parathyroid tissue (Xu et al, 2016). 
This procedure aims to remove all parathyroid glands that can be identified 
and simultaneously auto transplants a small portion of a gland to a new, non-
anatomic site (such as into a pocket created in the brachio-radialis or 
sternocleidomastoid muscles). Often, this procedure is accompanied by 
bilateral cervical thymectomy to ensure removal of supernumerary glands 
and parathyroid rests.  The disadvantage is that there is the potential for 
profound hypoparathyroidism and hypocalcaemia if the autograft fails to 
revascularize (Milas, 2016). Auto-transplantation involves mincing a portion 
of the most normal appearing excised gland into 1-2mm pieces (a total of 10 
to 15 pieces, or into slurry) which are then inserted into several muscular or 
subcutaneous pockets (Milas, 2016). Variations of this technique have been 
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described, including inserting each piece into an individual pocket, inserting 
several pieces into a pocket or injecting a suspension of fragments into a 
muscle with a syringe (Echenique-Elizondo et al, 2007, Milas, 2016). 
The brachio-radialis muscle of the non-dominant forearm, 
sternocleidomastoid muscle, pre-sternal chest as well as the subcutaneous fat 
of the abdomen are potential sites for re-implantation.  The advantage of 
implantation in the non-dominant forearm is that re-exploration (if needed) 
can be readily carried out under local anaesthesia (Milas, 2016). It also 
provides the ability to determine if an autograft is functional by comparing 
PTH levels of blood samples drawn from the antecubital vein of the 
implanted arm versus the contralateral arm (Milas, 2016). 
Sternocleidomastoid muscle implantation has an advantage as it is in 
the operative field of parathyroid surgery. However, compared to forearm 
autografts, neck autografts are more difficult to retrieve at reoperations, and 
could potentially confound imaging studies performed in search of 
supernumerary glands in the neck (Milas, 2016). In all cases, the site 
of reimplantation should be marked with metallic clips or non-absorbable 
sutures so that it can be identified in case of re-intervention (Lorenz et al, 
2015). The only prospective randomized trial comparing the outcomes of 40 
patients with either TPTX + AT and ST-PTX 
demonstrated significantly reduced rates of recurrence, significantly more 
often normalization of serum calcium and alkaline phosphatase as well as 
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significant improvement of clinical signs like pruritus and muscle weakness 
in the TPTX + AT group (Rothmund et al, 1991). Regarding recurrence 
rates, several retrospective case and cohort series report 0-85% for TPTX + 
AT (Lorenz et al, 2015).   
 
7.3 Total parathyroidectomy without auto-transplantation  
During this procedure, at least four parathyroid glands are resected, and 
unilateral thymectomy is usually performed if fewer than two glands are 
detected at regular positions at the respective side. It aims for near complete 
abolishment of PTH, and is widely practiced in countries such as Japan 
(Lumachi and Basso, 2014). The concept offers the advantage of a highly 
standardized procedure with smaller uncertainty regarding adequate size and 
function of parathyroid remnants (Lorenz et al, 2015). Because TPTX has 
the highest risk of causing permanent hypocalcaemia, permanent 
hypoparathyroidism and possibly adynamic bone disease, it is normally 
reserved for patients who suffer from severe complications of 
hyperparathyroidism due to lifelong dialysis (e.g. renal osteodystrophy) and 
preferably with facilities for parathyroid cryopreservation if possible (Milas, 
2016). TPTX should be generally contraindicated in patients who have a 
better chance of receiving renal transplantation 
due to iatrogenic hypoparathyroidism and hypocalcaemia post 
transplantation (Komaba et al, 2017). In a recent randomized trial of 100 
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patients comparing TPTX + AT and TPTX, at three years post-operative, 
patients who had TPTX had lower PTH levels (31.7 +/- 43.6 vs 98.2 +/- 
156.8 pmol/l) and lower rates of persistent (1.9 vs 4.1%) or recurrent (0 vs 
8.3%) hyperparathyroidism (Schlosser et al, 2016).  A small scale 
retrospective study on 23 patients with TPTX demonstrated a better 
biochemical cure than ST-PTX (74% vs 63%) after median follow-up of 72 
months (Lorenz et al, 2006). Contrary to the arguments regarding imminent 
development of adynamic bone disease and difficult medical management 
after TPTX, follow-up after two years demonstrated no clinical evidence of 
adynamic bone disease. The possible higher risk of 
developing adynamic bone disease and secondary calciphylaxis from 
calcium therapy must be carefully determined during long term follow-up in 
patients devoid of PTH excretion (Lorenz et al, 2015, Lorenz et al, 2006). 
However, presently, data is limited to evaluate merits and risks of this 
procedure to recommend it outside of controlled trials (Lorenz et al, 2015).    
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Chapter 8: Cinacalcet is associated with 
severe intraoperative and post-operative 
acute hyperkalaemia associated with 
hypocalcaemia after parathyroidectomy 
for renal hyperparathyroidism 
Abstract 
Objective: An impression that patients with prior treatment with cinacalcet 
and undergoing parathyroidectomy for renal hyperparathyroidism had 
greater acute hyperkalaemia and hypocalcaemia intraoperatively and 
immediate postoperative period prompted this study.  
Methodology: A single institution study was performed between January 
1993 and September 2014. Sixteen patients were on cinacalcet prior to 
parathyroidectomy, and 88 patients were controls.  
Results: 81.25% of the cinacalcet group recorded an intraoperative or 24 
hour postoperative potassium value ≥6.00mmol/L compared to 1.67% in the 
controls (P<0.001). 75% of cinacalcet patients had a potassium rise of 
≥1mmol/L from preoperative value compared to 10% (P<0.001). This was 
correlated with greater median percentage rise of potassium from 
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preoperative value in the cinacalcet group (33.33% vs. 11.54%, P<0.001).  
Cinacalcet patients also had greater degree of hypocalcaemia 24 hours 
postoperatively (2.10 ± 0.23 vs. 2.25 ± 0.26 mmol/L, (P< 0.01)) and greater 
need for intravenous calcium (93.75% vs. 50%, (P < 0.001)). 
Conclusions: This is the first report of acute rise in potassium seen in the 
intraoperative/immediate postoperative periods following parathyroidectomy 
in patients on cinacalcet for renal hyperparathyroidism. Clinicians should be 
alerted to this risk of hyperkalaemia so as to prevent morbidity and mortality. 
Key words: cinacalcet, hyperkalaemia, hypocalcaemia, parathyroidectomy, 
renal hyperparathyroidism. 
8.1 Introduction 
Secondary and tertiary hyperparathyroidism are frequently observed in 
patients with end-stage renal failure (ESRF). The progressively falling 
glomerular filtration rate results in hyperphosphataemia, hypocalcaemia and 
reduced levels of circulating 1, 25-dihydroxyvitamin D3 (calcitriol) due to 
renal failure (Ghani and Baxter, 2012). The latter leads to increase secretion 
of parathyroid hormone (PTH) and diffuse parathyroid hyperplasia 
(Wirowski et al, 2013, Meyers et al, 2009). Eventual progression leads to the 
development of nodular hyperplasia, and a decrease in the number of vitamin 
D receptors and calcium sensing receptors (Meyers et al, 2009). This 
hyperparathyroidism results in increased morbidity and mortality from renal 
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osteodystrophy, soft tissue and vascular calcifications, dyslipidaemia, 
hypertension and cardiomyopathy (Ghani and Baxter, 2012).  Currently, 
hyperparathyroidism from ESRF is predominantly managed medically, with 
a combination of phosphate binders, active vitamin D analogues, calcium 
and/or calcimimetics. Approximately 29% of ESRF patients undergo 
parathyroidectomy (PTX), which is primarily reserved for symptomatic 
patients with elevated PTH despite optimal medical therapy (Bajaj et al, 
2011, Lafrance et al, 2013). Procedures such as subtotal and total PTX with 
or without sternocleidomastoid or forearm autograft continue to be the 
primary therapeutic options for refractory cases in Australia, Europe and 
United States (Zitt et al, 2011). The definitive treatment is renal 
transplantation; however, in nearly a third of these patients, the 
hyperparathyroidism is not resolved and persists even several years after 
transplantation, occasionally requiring PTX (Guerra et al, 2011). Cinacalcet 
hydrochloride (cinacalcet), also known by its trade name Sensipar (Amgen, 
Thousand Oaks, CA) is a calcimimetic that has been approved for use in 
secondary hyperparathyroidism since 2004 (Norman et al, 2012). It reduces 
PTH secretion by acting as a calcium receptor agonist as well as by 
increasing the sensitivity of calcium-sensing receptors, upregulating calcium-
sensing receptor expression, and inhibiting parathyroid cell proliferation (Zitt 
et al, 2011, Tsuruta et al, 2013). Cinacalcet is reported to be generally well 
tolerated and labelled the new “medical parathyroidectomy” with nausea, 
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vomiting and diarrhoea as the most frequent adverse reactions (Ghani and 
Baxter, 2012, Wirowski et al, 2013). However, some patients who have been 
on cinacalcet discontinue their therapy due to adverse reactions or are 
resistant to its effects, potentially due to more aggressive disease and require 
PTX. The present study arose from observations that patients who were on 
cinacalcet for renal hyperparathyroidism and had subsequently undergone 
PTX developed more severe acute hyperkalaemia in the intraoperative and 
postoperative periods compared with those who were operated with 
traditional medical therapy. Specifically, the authors sought to determine 
whether there was any difference between these two groups of patients and if 
so, whether there was any correlation in the degree of intraoperative and 
postoperative hyperkalaemia and hypocalcaemia.  
8.2 Patients and Methods 
8.2.1. Study Population 
A retrospective, single institution review of all patients who underwent PTX 
for hyperparathyroidism was conducted at The Canberra Hospital, Australian 
National University Medical School from January 1993 to September 2014.  
Only patients who underwent PTX for renal hyperparathyroidism were 
eligible for inclusion in the study. At this institution, PTX was only offered if 
patients failed optimal medical management (which included calcitriol, 
calcium carbonate and phosphate binders). The exclusion criteria in this 
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study were (1) primary hyperparathyroidism; (2) subtotal parathyroidectomy 
(to negate the effect of residual PTH secretion on calcium measurements); 
(3) previous parathyroid surgery; (4) histopathological diagnosis other than 
hyperplasia, such as parathyroid carcinoma, (5) patients who are not dialysis 
dependent and have functioning renal transplant and (6) patients where 
potassium was administered in the intraoperative/postoperative day 0 period. 
Of the 386 patients who underwent PTX in the study period, 147 had renal 
hyperparathyroidism of whom 133 were operated by the first author. Of the 
104 patients that met the inclusion criteria, 88 were controls on traditional 
medical therapy such phosphate binders, active vitamin D analogues and/or 
calcium, and 16 had cinacalcet on top of traditional therapy prior to PTX, 
and these patients were operated between 2007-2014. The charts were 
studied for the following variables: age, sex, type of procedure, 
histopathology, total weight and volume of the parathyroid glands (volume 
was calculated using the formula for an ellipsoid Vol=4/3 πabc. Laboratory 
parameters analysed in the perioperative period included 25-hydroxy vitamin 
D, PTH, potassium, corrected calcium, phosphate, magnesium, urea, 
creatinine and alkaline phosphatase until 144 hours post-operative. 
Generally, preoperative measurements were taken within 12-24 hours before 
surgery, intraoperative values were taken every half hourly when recorded, 
and postoperative values were taken 6-8 hourly till 48 hours postoperative 
and 8-24 hourly for postoperative 48 hours to 144 hours. 
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Patients were dialysed for medical optimization one day prior to PTX and for 
most cases, the preoperative biochemical variables were taken some hours 
after this. Patients who were on cinacalcet had their medication variably 
discontinued prior to surgery. Total PTX with auto-transplant to 
sternocleidomastoid/brachioradialis muscle was complete in the study 
population. Anaesthesia for PTX did not differ significantly between patients 
and followed anaesthetic protocol: induction drugs were generally propofol, 
fentanyl and atracurium; maintenance was achieved with 
oxygen/sevofluorane mixture, fentanyl was given intraoperatively for 
analgesia and glycopyrrolate/neostigmine at the end of surgery. 
Insulin/dextrose and/or calcium gluconate/chloride were given 
intraoperatively and resonium (a cation exchange resin for hyperkalaemia) 
was given postoperatively when potassium
 
was greater than 6.00mmol/L. 
Postoperatively, patients were on varying doses of calcitriol and/or calcium 
carbonate three to six hourly, depending on the severity of hypocalcaemia 
and at the discretion of the surgeon. In addition, if corrected calcium was less 
than 1.9mmol/L, intravenous (IV) calcium gluconate/chloride was infused 
for one to two hours and repeated whenever indicated, and was used as a 
proxy for profound hypocalcaemia. 
8.2.2. Statistical analysis 
According to the variable distribution, a Student t test was used to compare 
the groups. A chi-square test was used to compare proportions (percentages). 
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Continuous variable data were reported as mean ± standard deviations (SD). 
For all analysis, p value 0.05 was considered statistically significant. All 
analyses were done using SPSS Statistics Software, and Microsoft Excel 
2010 (Redmond, WA, USA). 
8.3 Results 
8.3.1. Baseline characteristics 
The baseline characteristics, including patient demographics and 
preoperative laboratory data of control and cinacalcet groups are presented in 
Table 1. There was no significant difference in gender, however the 
cinacalcet group were significantly younger (44.38 ± 14.22 years) than the 
controls (52.30 ± 14.24 years). All other major preoperative variables were 
not significant between the two groups. 
8.3.2. Cinacalcet is associated with a greater rise in potassium in the 
intraoperative and the first 24 hour postoperative periods 
Figure 20 demonstrates a scatter plot of preoperative and the highest 
intraoperative/24 hour postoperative potassium concentrations in the 
cinacalcet and control patients. Twenty eight out of eighty eight patients 
from the control group did not have intraoperative or postoperative day 0 
potassium values recorded. 81.25% (n=13/16) of the cinacalcet group 
recorded an intraoperative or 24 hour postoperative potassium value 
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≥6.00mmol/L, compared to 1.67% (n=1/60) in the controls (P<0.001). More 
importantly, 43.75% (n=7/16) of the cinacalcet group registered an 
intraoperative or 24 hour postoperative potassium value ≥7.00mmol/L 
whereas no control patients reached this value. Overall, 75% (n=12/16) of 
cinacalcet patients had a potassium rise of ≥1mmol/L from preoperative 
value compared to 10% (n=6/60) (P<0.001). The average change in 
potassium from preoperative and intraoperative/24 hour postoperative in the 
cinacalcet group was +1.49 ± 0.92mmol/L versus +0.15 ± 0.63mmol/L, 
(P<0.001).   
The percentage change of serum potassium from preoperative to highest 
intraoperative/24 hour postoperative of those that had a positive change in 
the cinacalcet (n=15/16) and control patients (n=37/60) is illustrated as a Box 
and Whisker Plot in Figure21. Overall, the positive percentage change was 
greater in the cinacalcet group compared to controls (P<0.001). The values 
ranged between 5.88-69.05% in the cinacalcet and 0-38.89% in the controls. 
The 25
th
, 50
th
 and 75
th
 percentile changes of the cinacalcet patients was 
18.59%, 33.33% and 43.92% respectively compared to 5.88%, 11.54% and 
15.38% respectively for the control patients.  
Table 2 provides detailed information of patient characteristics, serial 
potassium levels and interventions undertaken for each of the cinacalcet 
patients. Typically, these patients have been on cinacalcet for 19.18 ± 16.66 
months at a dose between 30-180mg/day, at the discretion of the 
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nephrologist. Eight patients had intraoperative potassium readings. Notably, 
patient 6 registered potassium of 7.10mmol/L after removal of the fourth 
parathyroid gland and was given 10 units of insulin, 50% dextrose in 50ml 
and 10ml of 10% calcium gluconate. Patient 12 had the first intraoperative 
potassium reading of 6.40mmol/L at the time of removal of first parathyroid 
gland at which 50% dextrose and 10 units of insulin in 50ml were given 30 
minutes later. Despite this, the potassium level elevated to 6.70mmol/L by 
the time of removal of the fourth parathyroid glands requiring further IV 
50% dextrose and 10 units of insulin in 50ml as well as 10mls of calcium 
chloride (6.80mmol/L) was given. Patient 15 had an intraoperative potassium 
of 6.80mmol/L after the removal of the fourth parathyroid gland, and was 
given 10 units of insulin and 50% dextrose in 50ml. Two patients recorded 
peaked electrocardiogram T-waves: patient 6, during the intraoperative 
period and patient 15 seven hours after PTX. All of the cinacalcet patients 
recorded acute hyperkalaemia in the postoperative period, during which 
15/16 patients required dialysis in the first 24-48 hours postoperative period, 
and all patients were given a combination of dextrose, insulin and/or IV 
calcium and in some patients, resonium. 
Figure 22 demonstrates the relationships between preoperative PTH 
(provided as four quartiles) and mean highest intraoperative/24 hour 
postoperative potassium with respect to the proximity cinacalcet was ceased 
prior to surgery. There appeared to be no obvious relationship between (1) 
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PTH quartiles and the serum potassium levels in the group representing 
proximal cessation of cinacalcet and (2) serum potassium levels in the 
highest PTH quartile between the groups representing proximal and distal 
cessation of cinacalcet. This suggested that intraoperative PTH and the 
proximity of cessation of cinacalcet prior to surgery were probably 
independent variables. 
8.3.3. Cinacalcet is associated with greater need for IV calcium 
postoperatively and prolonged hospital stay 
Significantly greater proportion of cinacalcet patients required IV calcium to 
control hypocalcaemia in the postoperative period than control patients 
(93.75% vs. 50%, (P < 0.001)) (Table 1). The postoperative hospital stay 
was extended in the cinacalcet patients (7.73 ± 2.73 vs. 5.81 ± 2.76 days, (P 
<0.01)) due to complex management of prolonged hypocalcaemia, despite 
medical intervention.  
8.3.4. Cinacalcet is associated with greater hypocalcaemia and increased 
bone turnover 
Cinacalcet patients had lower mean preoperative corrected calcium level 
(2.49 ± 0.32 vs. 2.57 ± 0.20 mmol/L, (P>0.05)) and had larger percent 
reduction 24 hours after operation compared to controls (15.56% vs 11.95%) 
(Figure 23). The cinacalcet group maintained hypocalcaemic levels (normal 
lower range 2.10 mmol/L) 24 hours (2.10 ± 0.23 vs. 2.26 ± 0.26 mmol/L, 
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(P< 0.01)), 48 hours (1.90 ± 0.20 vs. 2.13 ± 0.26 mmol/L, (P<0.001)), 72 
hours (2.09 ± 0.21 vs. 2.20 ± 0.29 mmol/L, (P>0.05)), 96 hours (2.02 ± 0.20 
vs. 2.21 ± 0.29 mmol/L, (P<0.01)) and 120 hours (2.10 ± 0.17 vs. 2.23 ± 
0.31 mmol/L, (P>0.05)) after surgery relative to controls, most of whom 
maintained normocalcaemia with oral calcium and calcitriol in the 
postoperative period. 
Alkaline phosphatase concentrations between preoperative and postoperative 
day 5 demonstrated an overall increasing trend in both groups following 
PTX. Alkaline phosphatase levels in the cinacalcet group was greater during 
the preoperative (324.25 ± 264.98 vs. 239.51 ± 219.10 U/L, P>0.05)) and 
postoperative periods at 24 hours (329.79 ± 301.69 vs. 198.27 ± 136.36 U/L, 
(P<0.05)), 48 hours (317.31  ± 292.82 vs. 231.24 ± 205.98 U/L, (P>0.05)), 
72 hours (329.42 ± 302.70 vs. 229.09 ± 188.06 U/L, P>0.05)), 96 hours 
(396.8080 ± 390.81 vs. 300.77 ± 278.63 U/L, P>0.05)), and 144 hours 
(502.23 ± 491.71 vs. 375.41 ± 377.75 U/L, P>0.05)). 
8.4 Discussion  
Cinacalcet, a class II calcimimetic drug that reduces production of PTH, 
gained approval from the Food and Drug Administration for use in patients 
with ESRF in March 2004, and is well studied in this group of patients 
(Lazar and Stanus, 2007, Urena et al, 2009, Bover et al, 2009). In Australia, 
following approval for its use soon after that, the number of patients with 
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ESRF referred for surgical PTX fell. This was best demonstrated by the 
number of patients operated in our institution in the past eight years, 
whereby eighteen patients were operated for renal hyperparathyroidism in 
2005 versus only five patients in 2013. This has also been observed in other 
institutions (Lafrance et al, 2013, Cunningham et al, 2005, Li et al, 2011). In 
this institution, patients waiting for PTX nowadays had been exposed to 
cinacalcet for varying periods since 2007. 
After PTX, the study group demonstrated more severe and prolonged 
hypocalcaemia and acute hyperkalaemia, greater requirement for 
insulin/dextrose and IV calcium. Sudden removal of PTH by PTX appeared 
to severely diminish mobilisation of skeletal calcium with resultant 
hypocalcaemia, and an associated acute rapid rise of serum potassium, the 
cause of which is undetermined. It was expected the level of serum 
potassium would have risen higher without the use of insulin/dextrose. 
Critical incident review, in one patient, of the events during surgery and the 
immediate post- operative day, clearly demonstrated that some patients 
treated previously with cinacalcet may respond differently from those not 
exposed to the medication (Table 2). This patient developed severe 
intraoperative hyperkalaemia of 7.10mmol/L with tall peaked t-waves. This 
required urgent IV insulin/dextrose in the operating room twice to reduce the 
serum potassium. This level of acute hyperkalaemia occurred as soon as the 
fourth parathyroid gland was removed. The arterial blood gas demonstrated a 
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severe fall of ionised calcium and three doses of calcium chloride were given 
IV to correct this deficit. Four hours after the surgery, the patient 
redeveloped hyperkalaemia, requiring immediate haemodialysis.  
Suspecting that this pattern of electrolyte changes occurred more commonly 
with patients treated with cinacalcet previously, the authors reviewed the 
literature and found a report of mortality in a patient undergoing PTX for 
secondary hyperparathyroidism due to ESRF (Zahoor et al, 2012). This 
patient was one of a cohort of patients reported in a subsequent series 
demonstrating marginally more severe hyperkalaemia following PTX. 
Unfortunately, no data was available in that paper on the status of whether 
patients had been treated with cinacalcet prior to PTX, nor the serum calcium 
concentrations intraoperatively and postoperatively (Bajaj et al, 2011, 
Zahoor et al, 2012). 
Meyers et al noted similar findings whereby in patients who had undergone 
PTX, cinacalcet use preoperatively led to lower postoperative calcium and 
greater requirements for IV calcium infusion postoperatively compared with 
those who did not receive it (Meyers et al, 2009). However, they did not 
comment on the more significant finding of severe hyperkalaemia as had 
been reported in one other study (Bajaj et al, 2011, Zahoor et al, 2012).  
The results from our cohort of sixteen patients showed that patients treated 
with cinacalcet had greater reductions in serum calcium after PTX, and 
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required more IV calcium, with their hospital stay significantly longer. The 
most significant change however was a potassium elevation of > 
6.00mmol/L observed in 81.25% (n=13/16) of these patients, even as soon as 
after removal of the first two parathyroid glands, and more so with all 
parathyroid glands removed. This hyperkalaemia may lead to cardiac 
arrhythmia, possibly accounting for the death reported in one study (Bajaj et 
al, 2011, Zahoor et al, 2012). Our study shows how it is critical to closely 
monitor patients undergoing PTX, irrespective of whether they had been 
treated with cinacalcet or not, as in the earlier years, some patients not on 
cinacalcet reported hyperkalaemia. However, the incidence was much lower 
as seen in our data and other studies (Bajaj et al, 2011, Cruz and Perazella, 
1997). Between the two groups (other than the introduction of cinacalcet) 
there does not appear to be any major changes to the management of renal 
hyperparathyroidism. There were no changes in dialysis schedules (as the 
patients were appropriately dialysed 1 day prior to operation), the anaesthetic 
drugs used peri-operatively were on the whole, consistent, and the 
management of hyperkalaemia followed local protocol, which had not 
altered in the study period. 
The results of this study suggest that the two events, hyperkalaemia and 
hypocalcaemia, may be interrelated.  Although there is no confirmation, the 
authors propose that the cinacalcet patients had more profound hungry bone 
syndrome following parathyroidectomy. This is probably, in part, due to this 
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group of patients having greater duration of dialysis prior to surgery (Table 
1), perhaps due to the partial control of PTH levels, delaying referral for 
parathyroidectomy by the nephrologists.  During dialysis, it is proposed that 
the bones probably underwent further demineralization. Thus, at the time of 
surgery, rapid onset of hypocalcaemia triggered by parathyroidectomy from 
severe hungry bone syndrome may have led to efflux of potassium from the 
cells, to maintain electrical neutrality. We put forward the view that 
cinacalcet should be ceased before surgery, although the number of weeks 
prior to PTX when cinacalcet should be ceased is uncertain.  
 
Cinacalcet has a half-life of 30-40 hours, is metabolized by the cytochrome 
P450 mixed oxidase enzyme system and 80% of the metabolites are excreted 
by the kidneys (Poon, 2005). The metabolites are inactive and not thought to 
affect calcium receptors. The study results show the association with 
cinacalcet exposure prior to surgery, but cast little insight as to mechanism of 
hyperkalaemia and hypocalcaemia. .This is shown in Table 3 whereby the 
highest intraoperative/24 hours postoperative potassium were not related to 
either the preoperative PTH value, nor proximity of cessation of cinacalcet. 
Nonetheless, hyperkalaemia occurred as early as the removal of the first 
hyperplastic parathyroid gland and continued as more glands are removed. 
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Surgical practice has altered at The Canberra Hospital where there is now a 
policy of intraoperative monitoring in all patients undergoing PTX for ESRF. 
We believe this has prevented unnecessary morbidity and possibly mortality 
by identifying sudden elevations of serum potassium in the intraoperative 
and immediate postoperative periods (Table 3). 
 
Although our findings are consistent in 16 cases, and are of clinical practice 
importance, we acknowledge the limitations of this study. 
 
 The sample size of the cinacalcet group was small in comparison to the 
control group. Postoperative serum potassium and calcium measurements 
were analysed at different times in the postoperative period. Episodes of 
hyperkalaemia or hypocalcaemia may have been overlooked. There was no 
intraoperative or immediate postoperative potassium recorded in some of the 
control patients, as hyperkalaemia in this group was not suspected. Lastly, 
the study was limited up to 144 hours postoperative period. 
 
8.5 Conclusions 
This is the first observational report of acute rise in potassium associated 
with hypocalcaemia observed in the intraoperative and immediate 
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postoperative period in cinacalcet patients who have had PTX for renal 
hyperparathyroidism. 
The mechanism is unknown. Future basic sciences, or clinical investigations 
to demonstrate a direct relationship between cinacalcet, hypocalcaemia, and 
hyperkalaemia would be required to explain this observation. Calcimimetic 
use is likely to increase world-wide, in patients with ESRF. Some of these 
patients on cinacalcet, or who have been treated with cinacalcet, will require 
PTX. Awareness of this phenomenon of severe hyperkalaemia associated 
with hypocalcaemia by surgeons, anaesthetists and nephrologists will 
minimise patient risk.  
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8.6 Figures and Tables 
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Figure 20. Preoperative and highest intraoperative/postoperative day 0 potassium values of cinacalcet and control patients. 
Horizontal axis denotes patients. Vertical dotted line delineates cinacalcet patients to the left, and control patients to the right. 
Horizontal dotted lines mark potassium concentration of 5.00mmol/L, 6.00mmol/L and 7.00mmol/L. Arrows indicate potassium 
concentration change between preoperative and intraoperative/postoperative day 0 values.
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Figure 21.  Box and Whisker Plots of positive percentage change in serum 
potassium from preoperative to highest intraoperative/postoperative day 0 in 
cinacalcet and control patients. 
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Figure 22. Mean highest intraoperative/postoperative 24 hour potassium 
between preoperative PTH quartiles in relation to proximity of cessation of 
cinacalcet prior to PTX 
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Figure 23. Preoperative and lowest postoperative corrected calcium values in 
control and cinacalcet patients. Vertical bars represent standard error. * 
P<0.05 versus controls. 
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Table 1. Patient demographics, preoperative laboratory and perioperative 
characteristics. 
Characteristic Total (n=104) Cinacalcet (n=16) Control (n=88) P Value 
Age (years) 51.08 ± 14.45 44.38 ± 14.22 52.30 ± 14.24 <0.05 
Sex (M:F) 54:50 10:6 44:44 NS 
Duration of dialysis (years) 4.60 ± 2.79 4.50 ± 2.83 3.98 ± 2.79 NS 
25-hydroxy vitamin D (ng/ml) 62.00 ± 19.36 58.67 ± 21.39 72.00 ± 8.49 NS 
Calcium corrected (mmol/L) 2.55 ± 0.22 2.49 ± 0.32 2.57 ± 0.2 NS 
Phosphate (mmol/L) 1.99 ± 0.58 2.02 ± 0.53 1.99 ± 0.59 NS 
Magnesium (mmol/L) 0.89 ± 0.19 0.97 ± 0.11 0.87 ± 0.20 NS 
Urea (mmol/L) 19.49± 8.15 20.76 ± 10.98 19.26± 7.58 NS 
Creatinine (umol/L) 785.52 ± 307.75 859.00 ± 349.07 772.01 ± 299.81 NS 
Alkaline Phosphatase (U/L) 252.80 ± 227.57 324.25 ± 264.98 239.51 ± 219.10 NS 
Volume of hyperplasia (mm
3
) 22210.97 ± 18062.14 14628.77 ± 9876.17 23533.44 ± 18863.53 <0.05 
Total weight of glands (g) 2.55 ± 1.78 2.37 ± 1.70 2.60 ± 1.82 NS 
IV calcium postoperatively 56.73% 93.75% (15/16) 50% (44/88) <0.001 
Postoperative stay (days) 6.10 ± 2.83 7.73 ± 2.73 5.81 ± 2.76 <0.01 
Data presented as mean ± SD. Abbreviations: ESRF, End stage renal failure; IV, intravenous; 
NS, Not significant. 
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Patient  Renal 
transplant 
(RTX) 
Cinacalcet 
duration 
(months) 
Daily 
Cinacalcet 
dose (mg) 
Cinacalcet 
taken off 
before 
surgery 
(months) 
Pre -
operative 
potassium 
(mmol/L) 
 
Intra-
operative 
potassium  
(mmol/L) 
Post-
operative 
potassium 
Day 0 
(mmol/L) 
First 
postoperative 
dialysis given 
IV insulin/dextrose 
and/or IV calcium given  
 
1 Nil 1.5 60 0 4.1 - 7.0 Yes- Within 24 
hours 
IV insulin/dextrose + IV 
calcium  
2  Nil 22 90 0 5.0 7.1, 6.5, 
5.7, 5.8 
5.4, 6.0, 5.6, 
6.1, 6.4, 4.9 
Yes-  Within 24 
hours 
IV insulin/dextrose + IV 
calcium 
3 Nil 20 30 0 4.2 - 7.1, 6.4, 6.5, 
4.4 
Yes-  Within 24 
hours 
IV insulin/dextrose + IV 
calcium 
4 Nil 15 30 0 5.0 - 6.0 Yes-  Within 48 
hours 
IV calcium only 
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5  Nil 5 - 0 5.7 - 5.3 Yes-  Within 48 
hours 
IV calcium only 
6 Nil 10 150 0.25 4.7 7.1 7.3, 7.4, 7.4, 
7, 5.6, 5.0 
Yes-  Within 24 
hours   
IV insulin/dextrose + IV 
calcium 
7 Nil 12.5 180 0.5 5.8 - 6.2 Yes-  Within 48 
hours 
IV calcium only 
8 Failed RTX 14 120 0.5 4.7 4.6, 5.1, 5 4.8, 5, 5.8, 
6.1 
Yes-  Within 48 
hours 
IV calcium only 
9  Nil 68 180 1 5.0 6.0, 5.2, 
5.0, 5.7, 5.6 
5.5, 5.6, 7.1, 
5.6, 6.2, 6.7 
Yes-  Within 48 
hours 
IV insulin/dextrose + IV 
calcium 
10 Nil 40 180 1 5.8 6.5, 6.2, 
5.7, 5.6 
6.7, 6.2, 5.0 Yes-  Within 24 
hours 
IV insulin/dextrose + IV 
calcium 
11 Failed RTX 6 30 1 6.4 - 7.5, 6.8, 6.3, Yes-  Within 24 IV insulin/dextrose + IV 
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Table 2. Perioperative characteristics of cinacalcet patients. Hyperkalaemia in our study is defined as >5mmol/L.
6.7, 3.9 hours calcium 
12 Failed RTX 14 30 1 5.1 6.4, 6.7, 5.6 5.6, 4.8, 6.8, 
3.0 
Yes-  Within 24 
hours 
IV insulin/dextrose + IV 
calcium 
13 Failed RTX 15 120 1 4.7 5.0, 5.0 5.1, 5.4, 5.3, 
5.9, 4.7 
Yes-  Within 48 
hours 
IV insulin/dextrose + IV 
calcium 
14 Nil 38 60 2 4.7 6.8 6.6, 6.4 Yes-  Within 48 
hours 
IV insulin/dextrose + IV 
calcium 
15 Nil 12 90 6 4.8 - 6.8, 7.0 Yes-  Within 170 
hours 
IV insulin/dextrose + IV 
calcium 
16 Nil 14 90 15 5.1 - 5.4 Yes-  Within 48 
hours 
IV calcium only 
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Table 3. Protocol for PTX in ESRF patients with renal hyperparathyroidism 
1. Dialyse patients 24 hours before 
operation 
2. Check serum potassium, calcium, 
magnesium, phosphate and alkaline 
phosphatase prior to operation 
3. On the day of operation, place a 
central line or peripherally inserted 
central catheter, and an arterial line 
before surgery 
4. Continuously monitor ECG for tall 
peaked t-wave, shortened QT 
interval, lengthening of PR interval 
and QRS complexes intraoperatively 
5. Analyse arterial blood for potassium 
and ionised calcium hourly and to 
time with the removal of first and 
fourth parathyroid glands 
6. (a) Administer 10 units of IV insulin 
in 50% dextrose in 50ml if serum 
potassium >6.0mmol/L 
(b) Administer additional dose of IV 
10% calcium gluconate in 10ml 
given over 10 minutes if (a) fails to 
reduce serum potassium level 
7. Consider admitting patient to high 
dependency unit after operation 
8. Monitor calcium, magnesium, 
phosphate and potassium every two 
hours in the first 24 hours 
postoperative period, and four 
hourly between postoperative 24-48 
hours period 
9. Administer oral calcium carbonate 
and calcitriol every three to six 
hourly and give bolus dose of IV 
calcium if corrected calcium < 1.90 
mmol/L 
10. Consider dialysis in the first 24 
hours if serum potassium is not well 
controlled by 10 units of IV insulin 
in 50% dextrose in 50ml and IV 
calcium. 
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.PART IV: THESIS SUMMARY AND 
CONCLUSIONS 
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Chapter 9: Summary and Conclusions 
Parathyroid surgery has come a long way since its discovery just over 160 
years ago. Sir Richard Owen is honoured for his discovery of parathyroid 
glands following several years of dissection in Rhinoceros carcasses between 
1850-1852. Notable physicians and surgeons have subsequently contributed to 
the body of knowledge through trial and error, and driven by curiosity and 
determination. Regrettably, early human research and medical practice 
sometimes was associated with patient morbidity and mortality. The case of 
Captain Charles Martell is an exemplar of this, highlighting the natural course 
of parathyroid disease and associated manifestations (skeletal manifestations, 
nephrolithiasis), the need for better localisation tools of parathyroid glands and 
requirement of an experienced parathyroid surgeon (he underwent seven 
operations), the presence of ectopically located parathyroid glands 
(mediastinum), the associated lethal postoperative complications of 
parathyroidectomy (tetany and laryngospasm) and most importantly,  the 
importance of involving patients in decision making (he had read about 
ectopically positioned parathyroid glands in the mediastinum in 
Acta Medica Scandinavica and managed to convince Cope and Churchill to 
explore his mediastinum just prior to his seventh and final parathyroid 
operation). Few patients in the annals of history have been studied as 
extensively as Captain Martell, who eventually succumbed from the natural 
course of his disease (nephrolithiasis).  
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There is a complex and systemic interplay between the parathyroid glands, 
bone, kidneys, intestines and skin on calcium, magnesium and phosphate 
homeostasis. Progress in basic biological science remains fundamental to 
foster clinical research and evidence based practice for better investigative 
tools, and treatment (medical and surgical. An example is the development of 
an immunoassay for measurement of parathyroid hormone by Berson and 
Yalow in 1963, which earned them the Nobel Prize in Physiology or 
Medicine. Another is the FDA approval in 2004 of cinacalcet as an alternative 
to parathyroidectomy in hyperparathyroidism.   
 
The incidence and prevalence of dialysis dependant end stage renal failure is 
increasing in the Western societies, and consumes a significant quantum of 
healthcare resources. Although the optimal treatment of end stage renal 
disease is renal transplantation, there are issues with kidney donor shortage, 
and toxicity of immunosuppressive medications. Parathyroidectomy is a 
proven useful treatment prior to renal transplantation to alleviate the 
symptoms of renal osteodystrophy.  
 
Following the introduction of cinacalcet, there has been a fall in the number of 
parathyroidectomy operations performed in our institution, and around the 
world. However, in patients exposed to cinacalcet and subsequently 
undergoing parathyroidectomy (due to refractory disease or cessation of 
cinacalcet due to side effects), we have demonstrated severe hyperkalaemia 
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and greater hypocalcaemia in the intraoperative and in the immediate 
postoperative period. The hyperkalaemia was significantly elevated to the 
extent of ECG changes, there was greater requirement of intravenous 
insulin/dextrose and for some, emergency dialysis. Cinacalcet patients 
required significantly greater amounts of intravenous calcium to correct 
hypocalcaemia. It remains speculative that the two events may be related 
perhaps to maintain serum electrical neutrality. Our findings resulted in a 
change in protocol for perioperative management of parathyroidectomy in 
renal hyperparathyroidism in our institution. Greater awareness from surgeons, 
anaesthetists and nephrologists is necessary to prevent morbidity and mortality 
in this group of patients. 
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